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Abstract

Cognitive and circadian dysfunction are common aspects of neuropsychiatric disease that
are often overlooked in disease models and treatment strategies. In this work, we first evaluated
the potential for cognitive enhancement in healthy adult mice by targeting a kinase involved in
regulation of the molecular circadian clock. We then developed and characterized a model of
neuropsychiatric disease that could present a target for rescuing circadian and cognitive deficits
using this treatment.
Time-of-day effects have been noted in a wide variety of cognitive behavioral tests, and
perturbation of circadian rhythms impairs hippocampus-dependent learning and memory. We
first asked whether casein kinase 1 (CK1) δ/ε inhibition might also be used to improve cognitive
performance in the absence of disease. The oscillation of both clock genes and learning and
memory-related genes in the hippocampus suggests that these rhythms might be targetable.
We used cognitive behavioral testing to determine whether chronic, short-term treatment
with the pharmacological CK1δ/ε inhibitor PF-670462 could improve performance. Our
behavioral results revealed improved performance in both Morris water maze and radial arm
water maze, as well as contextual but not cued fear conditioning. Our molecular results also
show a mild increase in phosphorylated extracellular signal-regulated kinase in the hippocampus
of mice treated with PF-670462. While the hippocampus is essential for learning and memory,
the amygdala also plays a role in both types of fear-based associative learning. We found an
increase in activity-regulated cytoskeleton-associated (Arc) protein expression in the right
amygdala of CK1i-treated mice exposed to an acute, negative learning experience. Previous
vi

studies show a critical role for Arc expression in synaptic plasticity and memory consolidation,
lateralized to the right amygdala for negatively-valenced learning events.
Our molecular results suggest that CK1δ inhibition may interact with learning and
memory systems in the hippocampus and amygdala to improve light cycle performance on
behavioral tasks dependent on these areas of the brain, even in the absence of major circadian
disruption. It is possible that this is due to a shift in the time-of-day efficiency of these processes
resulting from the period-lengthening effects of CK1δ inhibition, or from stabilization of period
proteins in the nucleus and subsequent stabilization of circadian rhythms.
After establishing the potential for PF-670462 to improve cognition, we next sought to
develop a relevant model of neuropsychiatric disease that might benefit from a treatment option
that addresses cognitive and circadian components.
The etiology of schizophrenia (SCZ) is complex, polygenic, and highly variable among
individuals. Cognitive impairment is a core component of disease symptomology and is
indicative of patient outcomes. This study evaluated a novel mouse model with disruptions in
two putative SCZ susceptibility genes with roles in neurogenesis and synaptic plasticity,
Disrupted-in-schizophrenia-1 (DISC1) and reelin (RELN). Heterozygous, haploinsufficient reeler
mice were bred with mice expressing dominant-negative c-terminal truncated human DISC1 to
produce offspring with both mutations: a transgenic model of impaired neurogenesis and
neuropsychiatric disease. We evaluated the construct and face validity of the model,
demonstrating SCZ-relevant behavioral alterations and underlying neuropathology.
HRM/DISC1 mice display some SCZ-relevant behavioral phenotypes. Prepulse
inhibition of the acoustic startle response is used as a translatable measure of sensorimotor gating
in both human and animal testing. We found a reduction in baseline startle response in
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HRM/DISC1 mice, as well as decreased prepulse inhibition. We found subtle alterations in
circadian rhythms in HRM/DISC1 mice, including longer circadian periods during a phase shift
and reduced bouts of voluntary wheel-running activity.
HRM/DISC1 mice have subtle cognitive and social behavioral alterations, displaying
poor performance on water maze and social recognition tasks, and have no apparent changes in
affect. The most striking behavioral findings are reduced exploratory behavior in the open field,
decreased mobility in other tests, and reduction in bouts of voluntary wheel-running activity.
These effects limit the ability of many of our behavioral assays to detect a potential cognitive
phenotype.
One of the most consistent clinical finding in SCZ patients is abnormal gamma band
oscillations. Gamma oscillations (~25-100hz) are generated and synchronized through inhibitory
feedback by fast-spiking parvalbumin+ interneurons onto pyramidal neurons during a range of
cognitive processes. We found a reduction in the total number of parvalbumin+ cells in the
medial PFC of HRM/DISC1 mice. Reduced inhibitory output by PV+ GABAergic interneurons
onto PFC pyramidal neurons could lead to behavioral deficits in the HRM/DISC1 mouse model.
Administration of the anxiolytic diazepam unexpectedly had paradoxical effects on HRM/DISC1
mice, failing to rescue the deficit in exploratory behavior we found in the open field test. As
diazepam acts directly on GABAA receptors, we followed up on this finding by investigating the
level of GABAA receptor subtype expression, finding increased expression of A1-containing
GABA receptors in the prefrontal cortex of HRM/DISC1 mice.
Defects in adult hippocampal neurogenesis have been reported in patients with SCZ and
in multiple animal models. We characterized the rate of neurogenesis, and the survival and
maturation of adult-born neurons in HRM/DISC1 mice. While we found a no changes in the
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number of immature neurons in the hippocampus of HRM/DISC1 mice, these cells had reduced
dendritic outgrowth. We also found an increased number of BrdU+ cells in the in the dentate
gyrus of the dorsal hippocampus of the HRM/DISC1 brain, a lower proportion of which were
NeuN-, indicating differentiation into non-neuronal cell types. Taken together, these results
indicate a similar rate of neurogenesis, but suggest that the processes underlying the survival and
maturation of adult-born neurons in the hippocampus are altered in the HRM/DISC1 brain.
Overall, we identified alterations in neuronal maturation and dendritic outgrowth in the
hippocampus, alterations in GABAergic cells in the prefrontal cortex, and a complex behavioral
profile best described by intact affect, reduced voluntary mobility, a strong sensorimotor gating
deficit, and subtle changes in cognition and circadian rhythms. These alterations may present a
target for treatment with chronotherapeutic interventions like CK1 inhibition.
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Chapter 1: Introduction and literature review of cognition and circadian rhythms

Introduction
In this work, we have examined altered cognition in two opposite and complimentary
contexts: improved cognition using pharmacological intervention, and disrupted cognition in a
model of a disease state. While we explored other aspects of behavior and molecular signaling in
each study, the connection and main area of interest is on cognition and its intersection with
circadian rhythms, and the potential for the use of chronotherapy in schizophrenia (SCZ).
Circadian alterations are common in many neuropsychiatric disorders, including in most cases of
SCZ, and yet they are frequently overlooked in treatment strategies and in the characterization of
animal models of disease.
In the first study, we investigated the potential for cognitive enhancement using
pharmacological inhibition of the casein kinase 1 (CK1) isoforms that are involved in the
maintenance of circadian rhythms. In the second study, we evaluated a novel rodent model of
neuropsychiatric disease that could present a target for the rescue of circadian or cognitive
disruptions using CK1 inhibition. We modeled gene-gene interaction as a two-hit model of SCZ:
disrupting the two putative schizophrenia (SCZ) susceptibility genes DISC1 and RELN.
These studies were designed in an outside-in approach: we first examined behavior and then
determined what anatomical and molecular changes underlie the alterations.
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A very short history of pioneering learning and memory studies
Experimental research on learning and memory was initiated in 1885 with Hermann
Ebbinghaus’ book Ueber das Gedächtnis (On Memory), and followed swiftly by studies
integrating genetics and memory in animal studies[1, 2]. Ivan P. Pavlov’s early contributions to
what is now referred to as classical conditioning are well-known and were followed by
experiments in maze learning conducted by psychologists. By the 1920s, the use of the rat as a
laboratory subject made experiments to selectively breed for intelligence economically and
temporally feasible, and these were pioneered by Edward C. Tolman and Robert C. Tryon[2].
With these early studies came the first considerations of the kind of experimental confounds that
are still essential for designing and interpreting rodent behavioral tests: how emotional, physical,
and motivational differences between individuals and strains may alter the results of these tests.
Researchers in the 1940s and 1950s utilized a strategy that persists to modern scientific practice,
conducting a range of behavioral assays to detect differences in learning, activity, and emotional
behavior to attempt to discriminate alterations in learning from confounds due to other behaviors.
Follow-up studies on the “bright” and “dull” strains of rats generated by Tryon moved toward
the question of mechanism, and in 1964 Rosenzweig suggested that the differences in
performance on maze tasks between the lines were consistent with differences in excitability and
sustained activity on the brain, after finding increased levels of cerebral acetylcholine and
serotonin[3].
More than a century of research has yielded vast improvements of our understanding of
learning and memory and the systems that underlie these processes. Fundamentally, learning and
memory cannot be directly measured, only inferred from our measurements of the outcomes of
behavioral assays. The studies in this thesis use several different learning and memory tests and
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addresses the considerations that are critical for choosing and designing this kind of
experimentation. A number of other behavioral assays are discussed, including those designed to
detect alterations in anxiety, affect, and locomotion, and those tests we use ostensibly as control
experiments to detect confounding factors. However, the work presented here uses only a few of
the available learning and memory assays and leave questions to be answered by future work. In
addition to behavior, molecular evidence is presented for alterations in learning and memory
related systems, including inhibitory/excitatory circuit disruption and altered adult neurogenesis
that may offer potential mechanisms for the behavioral phenotype of a novel model for SCZ.
The circadian clock
The following study is directed specifically to investigate the interaction between
circadian rhythms and cognition. Before asking how cognition might be affected by potential
disease risk factors, we asked whether it might be possible to affect cognition in a healthy brain
by manipulating proteins involved in the maintenance of circadian rhythms. We began with a
behavioral assessment and then correlated the behavioral phenotype with molecular alterations
that hint at mechanisms for these changes.
While the presence of aberrant circadian rhythms in neuropsychiatric disorders is
common and studies designed to understand and correct these defects are a logical step,
understanding the circadian clock as a target for cognitive enhancement in the healthy brain
requires a brief review of the connections between circadian rhythms and learning and memory.
The endogenous circadian timing system is ubiquitous, enabling the coupling of an
organism’s behaviors and physiology with the external environment[4]. These rhythms respond
to cues (termed zeitgebers) to entrain to the environment, the most prominent being light, which
coordinates these functions with the day-night cycle. These rhythms maintain a temperature-
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stable period length near 24 hours even in the absence of external cues[5]. The suprachiasmatic
nucleus (SCN) in the hypothalamus serves as a circadian pacemaker[6], synchronizing the
rhythms of a large number of brain and peripheral oscillators. These oscillators are sensitive to
many zeitgebers in addition to light, including food cues, drug use, exercise, and hormonal
signals[7].
The molecular clock
Oscillations in the SCN and other oscillators are driven by interacting
transcriptional/translational feedback loops (TTFL)[8]. The negative feedback loop requires
rhythmic transcription of Period1-3 (PER) and Cryptochrome1-2 (CRY) genes by the
heterodimeric transcription factors Brain and Muscle ARNT-Like-1 (BMAL1) and Circadian
Locomotor Output Cycles Kaput (CLOCK). PER and CRY proteins are transcribed and
translocated into the nucleus where they act as negative regulators of the own transcription,
while PER2 enhances BMAL1 transcription to form a positive-feedback loop. (For a review, see
Reppert and Weaver, 2001[9].) A number of kinases, including casein kinase 1, function to
regulate the timing of these processes by phosphorylating PER proteins and affecting their
nuclear entry and degradation[10, 11], thereby influencing the rhythm of BMAL1 transcription
and BMAL1/CLOCK negative regulation.
Circadian rhythms in learning and memory
A wealth of studies across species have demonstrated distinct time-of-day effects on
memory acquisition[12]. These differences vary by species and the type of memory: for
example, rodent studies have shown better performance on maze navigation and contextual fear
conditioning tasks during the dark phase of a light-dark cycle, while cued fear conditioning is
more easily acquired during the dark phase. [13-15] There appears to be a bidirectional
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relationship between the difficulty of a cognitive task and its circadian influence – tasks with
higher cognitive load can themselves serve as zeitgebers.[16] Recall ability has also been shown
to have a rhythm, with peaks often falling 24 hours from the time of acquisition[14], though
some studies have also identified 12 hour peaks in recall[17, 18].
While lesion studies have demonstrated that some rhythms of acquisition and recall
persist in the absence of SCN mediation,[19, 20] circadian disruption has profound effects on
learning and memory.[12] Rhythmic expression of the molecular components of the circadian
clock in the hippocampus provides evidence for a hippocampal oscillator,[21] though its
influence on learning and memory is still being investigated. A key hypothesis is that the
molecular components of the circadian clock in the hippocampus modulate molecular signaling
pathways involved in learning and memory.[22] Circadian modulation of plasticity-related
proteins has been demonstrated in many animal models, including C57Bl/6 mice, and has effects
on short-term memory, long term memory, and memory retrieval. Calcium calmodulindependent protein kinase IV (CAMKIV) is necessary for fear memory[23], and its rhythm has
been demonstrated in Wistar rats.[24] PER proteins appear to have important regulatory roles, as
phosphorylation of hippocampal cAMP response element-binding protein (CREB) is PER1
dependent, and hippocampal long-term potentiation (LTP) is deficient in PER1 and PER2
knockout mice.[25, 26] Activation of extracellular signal-regulated kinase/mitogen-activated
protein kinase (ERK/MAPK) pathway and CREB are essential points of convergence of the
signaling cascades involved in learning and memory[27], and are rhythmic in the
hippocampus.[28] Circadian disruptions or treatments that target PER proteins may exert their
effects by altering the regulatory effects of PER1 on ERK/MAPK-dependent phosphorylation of
CREB.[22, 29]
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Chapter 2: Inhibition of casein kinase 1 δ improves cognitive performance in adult
C57BL/6J mice

Heather Mahoney, Emily Peterson, Hannah J ustin, David Gonzalez, Christopher
Cardona, Korey Stevanovic, John Faulkner, Amara Yunus, Alexandra Portugues,
Amy Henriksen, Camden Burns, Cameron McNeill, Joshua Gamsby, Danielle Gulick

Abstract
Time-of-day effects have been noted in a wide variety of cognitive behavioral tests, and
perturbation of the circadian system, either at the level of the master clock in the SCN or
downstream, impairs hippocampus-dependent learning and memory. A number of kinases,
including the serine-threonine casein kinase 1 (CK1) isoforms CK1δ/ε regulate the timing of the
circadian period through post-translational modification of clock proteins. Modulation of these
circadian kinases presents a novel treatment direction for cognitive deficits through circadian
modulation. Here, we tested the potential for PF-670462, a small molecule inhibitor of CK1δ/ε,
to improve cognitive performance in C57BL/6J mice in an array of behavioral tests. Mice treated
with a dose specific to the δ isoform displayed better memory in contextual fear conditioning,
made fewer working memory errors in the radial arm water maze, and trained more efficiently in
the Morris Water Maze. These benefits were accompanied by increased expression of activityregulated cytoskeleton-associated protein (Arc) in the amygdala in response to an acute learning
paradigm. Our results suggest the potential utility of CK1δ inhibition in improving cognition.
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Introduction
Over the past two decades, the complex processes that underlie cognition have been
elucidated. These processes are profoundly affected by changes in innate circadian timekeeping
mechanisms[1], with time-of-day effects on cognitive performance persisting even in the absence
of external timing cues.[2-5] While disruption of daily sleep-wake patterns and cognitive
impairment frequently manifest in neurological disorders like Alzheimer’s disease.[6, 7],
circadian rhythm disruptions also occur in otherwise healthy individuals when the endogenous
circadian clock cannot adapt to a voluntary or involuntary shift in the timing of sleep.[8] The
structure of modern society imposes cognitive demands at all times of day, including those times
at which we are not primed for peak cognitive performance. This is common during jet lag, shift
work, and many school schedules, and is exacerbated by the sharp increase in the use of digital
devices at night and consequent exposure to wake-promoting blue light.[9-12] Alterations to
clock timing are associated with cognitive deficits [1], and increasing evidence suggests that
circadian rhythm disruption contributes to a number of other health issues as well.[13] Circadian
disruption is usually addressed through chronotherapy – interventions to correct the mismatch
between exogenous time and endogenous sleep timing in order to improve the ability to achieve
and maintain sleep.[14] Chronotherapeutics include behavioral therapies, such as strategic
exposure to specific wavelengths of light to realign the endogenous clock. [15] Melatonin,
benzodiazepines, and caffeine have also been effective in short-term jet-lag conditions, but
produce undesirable side effects and have limited efficacy for long term circadian disruption in
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shift workers.[16] In the current study, we investigate the use of a pharmacological intervention
that acts on circadian clock mechanisms to improve cognition in healthy adult mice.
The circadian clock is an endogenous system that controls the rhythmicity of
physiological and biochemical processes, thus enabling organisms to anticipate daily changes in
the environment. The master circadian pacemaker resides in the suprachiasmatic nucleus (SCN)
of the hypothalamus. The SCN conveys time-of-day information to peripheral oscillators,
including the hippocampus and amygdala, essential memory processing areas.[17-19] This
master circadian oscillator can be reset or “entrained” by exogenous cues called zeitgebers,
which allow the system to adapt to changes in the environment and keep circadian rhythms
aligned to their appropriate phase. At the molecular level, the mammalian molecular clock is
present in all nucleated cells and consists of internal, interlocked positive and negative
transcription-translation feedback loops.[20] At the core of the negative feedback loop are the
heterodimeric Brain and Muscle ARNT-Like (BMAL) and Circadian Locomotor Output Cycles
Kaput (CLOCK) transcription factors, which drive the expression of the negative regulator
Period (Per) and Cryptochrome (Cry) gene families.[20, 21] Once transcribed, PER and CRY
are ultimately translocated to the nucleus to repress their own transcription until their
proteasome-mediated degradation releases the molecular “brake” of the clock, allowing BMALCLOCK transcription to resume and resetting the 24 hour period.[22, 23] A number of kinases,
including the serine-threonine casein kinase 1 (CK1) isoforms CK1ε and CK1δ, modulate the
timing of the circadian period through post-translational modification of clock proteins.[24, 25]
Many studies have demonstrated time-of-day effects in a wide variety of cognitive
behavioral tests, across many different animal models (reviewed by Smarr et. al).[26]
Perturbation of the SCN or circadian rhythms impairs hippocampus-dependent learning and
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memory. While the SCN acts as the central pacemaker, a cell-autonomous clock has also been
identified in the hippocampus, driven by the SCN but capable of oscillating in isolation. [27, 28]
The hippocampus is essential for most forms of declarative learning and memory, and
hippocampal cells rhythmically express clock genes even in the absence of input from the
SCN.[19, 29, 30] In fact, PER2 is highly expressed in hippocampal pyramidal cells, and the
rhythm of its expression is nearly 180° out of phase with SCN expression patterns.[29, 31] Mice
with mutations in PER1 or PER2 have deficits in long-term memory, and PER2 -deficient mice
exhibit abnormal long-term potentiation and reduced phosphorylation of cAMP-responseelement-binding protein (CREB) in the hippocampus.[19, 29]
CK1δ inhibition increases nuclear retention of PER2, lengthens the circadian period, and
stabilizes disrupted circadian rhythms in arrhythmic genetic and environmental models.[32] Our
previous work demonstrates the ability of CK1δ/ε inhibition with the small-molecule inhibitor
PF-670462 to improve cognitive performance and reduce amyloid burden in a mouse model of
Alzheimer’s disease.[33] To expand our understanding of the effects of CK1 inhibition on
learning and memory systems, we examined changes in cognitive behaviors in wild-type (WT)
C57BL/6J mice during chronic, short-term treatment with PF-670462. Based on evidence that
CK1δ is the dominant regulator of circadian period length, and that inhibition of CK1δ stabilizes
circadian rhythms in mouse models of disrupted circadian timing, we chose to chronically treat
adult WT mice with 10mg/kg/day PF-670462 to preferentially inhibit CK1δ over CK1ε [32, 34]
To determine whether CK1δ inhibition can improve behavioral performance at a time of day in
which mice display poorer cognitive performance[1], we subjected mice to a battery of
behavioral tests during their normal rest phase in the light cycle of a 12/12 light:dark (LD) cycle,
including cognitive, affective, and motor tests. We hypothesized that daily treatment with a
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CK1δ inhibitor may increase performance on these tasks, especially multi-day tasks that disrupt
sleep-wake cycles over several days. To generate a snapshot of the expression of key circadian
and learning and memory proteins at the time of testing, we collected tissue and examined
BMAL1, PER1, PER2, phosphorylated extracellular signal-regulated kinase (pERK), and
glycogen synthase kinase 3 beta (GSK3β) expression in the hippocampus 24hr after the end of
behavioral testing. Finally, we presented a separate cohort of mice with an acute learning
experience and assessed the effects of CK1δ inhibition on the activation of activity-regulated
cytoskeleton-associated protein (Arc), an immediate early gene associated with memory, in the
hippocampus and amygdala.[35] We find that selective inhibition of CK1δ produces a mild
improvement in the cognitive performance of WT mice that is associated with an alteration in the
expression of learning and memory-related genes in the hippocampus and amygdala.
Results
To determine whether the cognitive performance of healthy, adult WT mice could be
improved by chronic inhibition of CK1δ with PF-670462, we treated 2-4 month old male
C57BL/6J mice with PF-670462 (CK1i, 10mg/kg/day) or vehicle (VEH, 20% b-cyclodextrin in
citrate buffer) at ZT10 (2 hours before lights-off) for 3 days, then began a battery of behavioral
tests and continued to administer VEH or CK1i at ZT10 daily throughout testing. We selected
male-only mice to prevent confounding effects of the estrous cycle.
While inhibition of CK1ε has a minimal effect on period length, selective inhibition of
CK1δ lengthens the period of behavioral rhythms.[32, 36] For this reason, we focused our
investigation on CK1δ inhibition, hypothesizing that cognitive performance rhythms and timeof-day gating of learning and memory in the hippocampus may also be altered. Our experimental
conditions were modeled after several studies that administered PF-670462 at or near ZT10 to
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correspond with peak CK1δ/ε activity in the SCN in order to generate the maximum effect on the
circadian phase. [32, 34, 37]
Whenever possible, our schedule of testing was designed to place the most stressful tests
at the end of the testing period, to avoid stress effects on cognitive behaviors. Because water
maze testing is also a stressor, we performed a sucrose preference test immediately following
radial arm water maze (RAWM) to detect stress-induced anhedonia. To minimize over-time
effects on our results and test primarily between ZT4-8, we split testing into multiple cohorts.
(Figure 2.1a-b)
Chronic, short-term treatment with PF-670462 causes no obvious adverse effects
We included several assays to determine whether chronic, short-term treatment with CK1i would
alter behaviors that might confound the results of our cognitive tests. To test for intact locomotor
activity and normal forelimb strength, which are essential for performance of the water maze
tasks, we used a two-trial rotarod test and measured forelimb grip strength. We found no
differences in locomotor ability on the rotarod (F(1,11)=0.9777,p=0.344) (Figure 2.2a), or in grip
strength (t(11)=1.687, p=0.1198) (Figure 2.2b). To ensure intact nociception and to rule out
stress-induced anhedonia, we confirmed that there were no differences in hot plate (t(11)=1.047,
p=0.3175) (Figure 2.2c), or sucrose preference tests(t(11)=0.3228, p=0.7529) (Figure 2.2d).
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Figure 2.1: Experimental design. (a) Cohort 1-3 schedule, consisting of 18 consecutive days of
ZT10 CK1i injections, and elevated plus maze (EPM), Morris water maze (MWM), Porsolt
forced swim test (FST), and fear conditioning (FC). (b) Cohort 4 and 5 schedules, consisting of
16 consecutive days of ZT10 CK1i injections, open field (OF), Ymaze, 6-arm radial arm water
maze (RAWM), sucrose preference test (SP), Rotarod, grip strength, and hot plate tests followed
by tissue collection. (c) Arc experiment schedule, consisting of 3 days of ZT10 CK1i injections
followed by a 5-shock fear conditioning learning paradigm, and tissue collection 1-hour posttraining.

We used the Porsolt forced swim test (FST) and elevated plus maze (EPM) to look for
differences in affect and anxiety. We found no differences in latency to immobility in the FST
(t(22)=0.8655, p=0.3961) (Figure 2.2e), or in the ratio of time spent in the open vs. closed arms
in the EPM (t(23)=0.5056, p=0.6179) (Figure 2.2f).
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Figure 2.2: Chronic, short-term treatment with PF-670462 causes no obvious behavioral deficits.
(a) Latency to fall from Rotarod over two trials (VEH: n=7 mice, CK1i: n=6 mice) (b) Forelimb
grip strength, presented as the average of three trials per mouse. (VEH: n=7 mice, CK1i: n=6
mice) (c) Latency (s) to hind leg lift on hot plate. (VEH: n=7 mice, CK1i: n=6 mice) (d) Percent
preference for a 2% sucrose solution over water in a two bottle, overnight test. (VEH: n=7 mice,
CK1i: n=6 mice) (e) Latency (s) to first bout of immobility in the forced swim test (VEH: n=12
mice, CK1i: n=13 mice) (f) Ratio of time in the open:closed arms of the elevated plus maze.
(VEH: n=12 mice CK1i: n=13 mice) Each dot represents a mouse. Data are represented as mean
± SEM.

PF-670462 improves contextual fear conditioning
To determine whether it is possible to use CK1δ inhibition to improve performance on
learning and memory tasks during a time of off-peak cognitive efficiency, we tested during the
light cycle and used several different behavioral tests for which day/night differences in
17

peak/nadir performance have been demonstrated in prior studies.[1] Our first set of experiments
included classical fear conditioning (FC) with both contextual and cued retrieval tests. In FC
training, both VEH and CK1i-treated mice increased their freezing behavior following the two
tone-shock pairings. (Figure 2.3a)

Figure 2.3: Mice treated with 10mg/kg PF-670462 display increased freezing behavior in
contextual fear conditioning but have normal training behavior and performance on the cued test.
(a) Freezing behavior over time during training. Dotted lines indicate presentation of tone-shock
pairing. (VEH: n=12 mice, CK1i: n=13 mice) (b) Freezing behavior in the contextual test (VEH:
n=12 mice, CK1i: n=13 mice) (c) Freezing behavior in the cued test (VEH: n=12 mice, CK1i:
n=13 mice) Each dot represents a mouse. Data are represented as mean ± SEM. *p<0.05,
Student's t-test with Welch’s correction

A repeated measures ANOVA demonstrated a significant effect of time (F(1.507, 33.15)
= 39.86, p<0.0001,) but not treatment (p=0.5626, F(1, 23) = 0.3451), and no time x treatment
interaction (F(6, 132) = 0.7735, p=0.5921). (Figure 2.3a) In the context test, the total percent
time freezing was higher in CK1i-treated mice (t(18.63)=2.658, p=0.0157) reflecting a large
effect of treatment on freezing in the test (Hedges’ g=1.04) (Figure 2.3b). There was no
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difference in the cued test, either before (t(23)=2.328, p=0.0573) or after (t(23)=1.543,
p=0.1365) the presentation of the conditioned stimulus. (Figure 2.3c)
CK1 inhibition with PF-670462 improves spatial learning
In our first set of behavioral tests, we also used Morris water maze (MWM) to measure
spatial learning and long-term memory retrieval. In the MWM, both groups trained successfully
to an escape latency of less than 20 seconds by day 5 of training. A repeated measures ANOVA
was significant for training day (F(2.414, 45.88) = 31.67, p<0.0001) and treatment (F(1, 20) =
9.365, p=0.0062), but not the interaction (F(4, 76) = 0.7439, p=0.5650). CK1i-treated mice found
the escape platform more quickly on the third (t(20)=2.4363, p=0.0243) and fourth
(t(19)=2.5911, p=0.0179) days of training. By day 5 of training, untreated mice had similar
escape latency to CK1i-treated mice (t(19)=1.8451, p=0.0807). (Figure 2.4a) We found no
difference in the amount of time spent in the target or opposite quadrant, or in the number of
entries to the target platform area in either the 24- or 72-hour probe tests. (Figure 2.4b-c)
Although the results from FC and MWM in our first set of behavioral tests both
suggested mild improvement in cognitive performance, we found a low effect size and wanted to
determine whether there were effects on other measures of hippocampus-dependent working
memory. We used radial arm water maze (RAWM) to examine both spatial and working
memory, and Y-maze to examine working memory in a different context. While group
differences over time for the 3 training days were not significant (Figure 2.4d-f), we found that
CK1i-treated mice made fewer working memory errors in the third trial of the final testing day
(t(16.27)=2.335, p=0.0327). (Figure 2.4g) There was also a trend toward fewer spatial memory
errors in CK1i-treated mice on this trial (t(23)=1.845, p=0.078) (Figure 2.4h).
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Figure 2.4: CK1 inhibition with PF-670462 improves spatial learning behavior but not recall in
the Morris water maze, and working memory performance in the radial arm water maze but not
Y maze. (a)Escape latency over 5 days of training in the Morris water maze (MWM). Dotted
line indicates goal latency of 20s. (b) Time spent in target and opposite quadrants of the MWM
pool during probe trials conducted 24 and 72h after the completion of training. (c) Number of
entries during the probe trials to the area of the pool that previously contained the escape
platform. (d) Escape latency from the 6-arm radial arm water maze (RAWM) over 4 days of
testing. (e) Working memory type errors over time in the RAWM. (f) Spatial memory type errors
over time in the RAWM. (g) Working memory type errors in RAWM in the final trial on the last
day of testing. (h) Spatial memory type errors in RAWM in the final trial on the last day of
testing. (i) Percent spontaneous alternation in the Y-maze. Each dot represents a mouse. Data are
20

represented as mean ± SEM. *p<0.05, #p>0.1
Despite making fewer working memory-type errors in the RAWM, CK1i-treated mice
made a similar number of spontaneous alternations as VEH-treated mice in the Y-maze
(t(18)=1.754, p=0.097) (Fig 5.4i), and made a similar number of total arm entries (t(19)=1.011,
p=0.325). The difference in groups comparisons between RAWM and Y-maze may be due to
differences between the tests: Y-maze relies on natural alternating behavior to reflect working
memory, while RAWM is dependent on the navigational memory over the course of several days
with the added factor of motivation to escape.
CK1 inhibition with PF-670462 may alter expression of pERK in the hippocampus
To uncover what mechanisms might underlie the improvements in performance that we saw in
some of the cognitive tests, we collected hippocampi from test mice and performed western
blotting to detect changes in the expression of circadian and learning and memory associated
proteins (Figure 2.5a). We euthanized the mice as close as possible to ZT6, the approximate
midpoint time that we performed our behavioral testing, and alternated groups to help prevent
time-of-day effects. We found a trend toward increased phosphorylated ERK; however, the
results were variable, and a Welch’s t-test showed that this difference was not statistically
significant (t(15.369)=3.552, p=0.079) (Figure 2.5b).
We also examined the “snapshot” expression of several circadian proteins in the
hippocampus during the time of behavioral testing to determine whether our behavioral results
could be explained by differences in the molecular circadian clock in the hippocampus. We
found no significant differences in the expression of PER1 (t(10)=1.484, p=0.169), PER2
(t(10)=-0.806, p=0.439), or BMAL1 (t(10)=0.042, p=0.967). (Figure 2.5c)
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Figure 2.5: CK1 inhibition may increase pERK expression in the hippocampus. (a)
Western blots for hippocampal pERK, PER1, GSK3β, PER2, BMAL1, and corresponding βactin. Representative blot images. Images have been cropped. Full length blot images in
Supplementary Figures 1A-F. Quantification of western blots for (b) pERK and GSK3β. pERK
results represent two separate normalized gels. (c) PER1, PER2, and BMAL1. Bands were
normalized to actin and expressed as fold change from vehicle group mean. Each dot represents
result from one mouse. Data are represented as mean ± SEM. #p=0.079
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Expression of Arc is increased in the right amygdala of CK1i-treated mice following
a negatively-valenced learning event.
To further investigate potential mechanisms for the improvement in behavioral performance, we
used an acute, 5 shock-tone pairing learning paradigm with a separate cohort of mice and
collected tissue precisely 1 hour after the end of conditioning (Figure 2.1c). This design allowed
us to examine the expression of Arc, which is transcribed following the release of norepinephrine
in response to learning and is essential for hippocampal long-term potentiation and aversive
memory formation in the amygdala.[38, 39](Figure 2.6a) Previous studies have demonstrated
that Arc expression is preferentially upregulated in the right amygdala following a negativelyvalenced emotional learning event. [35] A one-way ANOVA indicated no significant differences
in left amygdala Arc expression between VEH-treated mice maintained in the home cage with no
learning event (VEH+NL), VEH-treated mice exposed to the learning paradigm(VEH+L), and
CK1i-treated mice exposed to the learning paradigm (CK1i+L) (F(2,12)= 0.4719, p=0.6349)
(Figure 2.6b). However, we found significant group differences in right amygdala Arc
expression (CK1i+L) (F(2,12)= 15.18, p=0.0005); right amygdala Arc was significantly
upregulated in both VEH+L (p=0.0391) and CK1i+L(p=0.0004) groups compared to VEH+NL.
Arc expression in the CK1i+L group was also significantly higher than in the VEH+L group
(p=0.0436) (Figure 2.6c). We also found that the learning paradigm altered Arc expression in the
dorsal (F(2,12)=5.5166, p=0.0184) and ventral (F(2,13)=6.669447, p=0.0102) hippocampus.
While the learning paradigm increased Arc expression in the VEH group in both the dorsal
(p=0.0183) and ventral (p=0.0079) hippocampus, it was only increased in the CK1i+L group in
the dorsal hippocampus (p=0.0183), and we found no differences between VEH+L and CK1i+L
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treatment groups in either. Interestingly, Arc expression in the CK1i+L group was not
significantly increased from the VEH+NL group in the ventral hippocampus. (Figure 2.6d-e)

Figure 2.6: CK1i treatment increases arc activation in the right amygdala. (a) Western blots for
Arc and actin for mice in three groups: VEH treated and kept in home cage (VEH+NL), VEH
treated and exposed to an acute learning paradigm of 5 foot shocks in the fear conditioning
chamber (VEH+L), and CK1i treated and exposed to the acute learning paradigm (CK1i+L).
Representative blot images. Images have been cropped. Quantification of western blot results for
Arc in the (b) left amygdala, (c) right amygdala, (d) ventral hippocampus and (e) dorsal
hippocampus of mice in. Bands were normalized to actin and expressed at fold change from
vehicle group mean. Data are represented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001
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Discussion
The overexpression of CK1δ/ε in the human Alzheimer’s disease brain has driven
research interest in targeting CK1δ/ε for therapeutic intervention, and studies in multiple animal
models of AD have demonstrated the ability of CK1δ/ε inhibitors to stabilize circadian rhythms,
improve cognitive function, and rescue hippocampal proteomic alterations.[40-42] We have
previously shown that inhibition of CK1δ/ε with PF-670462 improves cognitive-affective
behavior in the APP-PS1 transgenic mouse model of AD. [42] With this study, we sought to
expand our understanding of how inhibition of these key circadian regulators might interact with
learning and memory systems in the absence of pathological deficits.
CK1δ/ε inhibition with PF-670462 lengthens the circadian period in cyclic 12:12 LD
lighting, despite expectations that light would act as the dominant zeitgeber in these conditions.
[43] The ability of CK1δ/ε inhibition to overwhelm light as the primary zeitgeber suggests its
potential utility to address circadian dysfunction by modulating oscillations. Studies
demonstrating the ability of CK1δ/ε inhibitors to alter peripheral clock gene rhythms have led to
the proposal that drugs might be developed to more efficiently phase-adjust circadian rhythms to
ease the effect of shift work or jet lag on metabolic processes.[44] Here, we asked whether
CK1δ/ε inhibition might also be used to improve cognitive performance in the absence of
disease. The oscillation of both clock genes and learning and memory-related genes in the
hippocampus suggests that these rhythms might be targetable.[1, 45]
Learning and memory efficiency is gated over the day-night cycle[4, 5, 46], and these
diurnally regulated effects on cognition persist even in the absence of light cues or other external
zeitgebers.[1, 3] Our molecular results suggest that CK1δ inhibition may interact with learning
and memory systems in the hippocampus and amygdala to improve light cycle performance on

25

behavioral tasks dependent on these areas of the brain, even in the absence of major circadian
disruption. It is possible that this is due to a shift in the time-of-day efficiency of these processes
resulting from the period-lengthening effects of CK1δ inhibition. However, there is some
disagreement in the results of previous studies on the rhythms of acquisition and recall in fear
conditioning, and some studies on C57Bl/6 mice with methodology most similar to ours show a
nadir of performance at night, and peak around ZT4. [3, 5, 47] Rodent water maze studies are
also somewhat inconsistent across species and methodology.[1] Because we found mild
improvements in several behavioral tests with different peak performance times, it’s more likely
that treatment with PF-670462 is interacting with the learning and memory mechanisms in some
other way. One possibility is that the treatment may have a stabilizing effect on circadian
disruption caused by behavioral testing undertaken during the rodents’ sleep cycle, as sleep is a
potent modulator of learning and memory.
While the effects of CK1δ/ε inhibition on circadian rhythms make modulation of the
hippocampal clock an intriguing explanation for our results, CK1 isoforms are widely distributed
and have a number of other functions in the brain. All major CK1 isoforms are expressed in the
cortex and striatum, and negatively regulate NMDA receptor-mediated glutamatergic synaptic
transmission in the cortex and striatum.[48] While multiple studies have shown that CK1δ/ε are
highly expressed in the hippocampus, to our knowledge there are no studies to date examining
the function of CK1 isoforms on synaptic transmission in the hippocampus.[49] Hippocampal
learning and memory is initiated by NMDA-mediated calcium influx and the downstream
activation of multiple signaling pathways, including the ERK and mitogen-activated protein
kinase (MAP) pathways. [50-52] Our results show a mild increase in pERK in the hippocampus
of mice treated with PF-670462. It is unclear whether this increase is due to alteration of the
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circadian phase of rhythmically expressed kinases in the hippocampus by the treatment, or
perhaps by more direct action of CK1δ inhibition on the regulation of synaptic transmission. We
found no differences in hippocampal expression of core circadian proteins PER1, PER2, or
BMAL1, which might suggest that CK1δ with PF-670462 has minimal effect on the molecular
circadian clock in the hippocampus. Time-course studies of circadian and learning and memory
protein expression in the hippocampus will be essential to uncovering the mechanisms behind
the cognitive effects of CK1δ inhibition.
Another possible explanation for the cognitive improvements with PF-670462 treatment
is direct action on learning and memory pathways. If CK1δ, an abundant serine-threonine kinase,
phosphorylates proteins involved in learning and memory cascades, its inhibition could lead to
downstream effects on behavior. For example, GSK3β is a recognized regulator of hippocampal
function and synaptic plasticity with an endogenous circadian rhythm in phosphorylation state in
area CA1 of the hippocampus.[53] While we found no significant change in the expression of
GSK3β in the hippocampi of our CK1i-treated mice, this does not rule out changes in inhibitory
phosphorylation that may underlie differences in day-night cognitive performance.[54]
The most promising evidence for a molecular correlate to the behavioral results we see in
this study is in the amygdala. We found an increase in ARC protein expression in the right
amygdala of CK1i-treated mice exposed to an acute, negative learning experience. Previous
studies show a critical role for ARC expression in synaptic plasticity and memory consolidation,
lateralized to the right amygdala for negatively-valenced learning events.[35, 55, 56] Our
behavioral results show increased freezing with PF-670462 treatment in contextual but not cued
fear conditioning, and while the hippocampus is essential for learning and memory, the
amygdala also plays a role in both types of fear-based associative learning. It seems likely that
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CK1δ inhibition, or its circadian sequelae, have effects on multiple brain areas and signaling
pathways.
While further work is needed to determine the precise mechanisms for how CK1δ
inhibition improves cognitive performance, our results suggest that treatment with PF-670462 or
other forms of chronotherapy may be effective not only as a treatment for cognitive symptoms
and circadian disruption in AD, but also in treating more subtle circadian-related cognitive
impairment. These results reflect the interactions between circadian and learning and memory
systems, and most interestingly, demonstrate cognitive enhancement in normal, healthy adult
mice which may be of significant translational value. Future studies should investigate the
mechanisms underlying this cognitive enhancement and focus on CK1δ inhibition as a tool to
better understand rhythmicity and circadian control of learning and memory systems.
Methods
Mice
We used male C57BL/6J WT mice from Jackson laboratory, aged 2-3 months at the
beginning of drug administration and behavioral testing. Studies we restricted to male mice to
reduce the number of mice necessary to complete the study while avoiding potentially
confounding effects of the estrous cycle. Mice were group housed in 12h LD in standard cages
and fed standard mouse chow and water ad libitum. All animal testing procedures and care
followed the NIH guidelines and were approved by the University of South Florida’s
Institutional Animal Care and Use Committee.
Pharmacological treatment
Mice were assigned pseudo-randomly to groups, and treated with either the casein kinase
1 inhibitor PF-670462 (10mg/kg, Cayman Chemical; Ann Arbor, MI) or vehicle (20% (2-
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hydroxypropyl)-β-cyclodextrin in 25mM citrate buffer, MilliporeSigma, Oakville, ON)
intraperitoneally once daily at ZT10 to correspond to peak CK1 activity in the SCN, beginning 3
days prior to the start of behavioral testing and continuing throughout.
Behavior
In order to assess the impact of treatment and genotype on learning and memory, we used
Fear Conditioning (FC), Morris Water Maze (MWM), Radial Arm Water Maze (RAWM), and
Y-maze. We also assessed anxiety and affect using Elevated Plus Maze (EPM), and Porsolt
Forced Swim Test (FST). FST was also used as a control for swimming ability. Behavioral
testing began on day 4 of treatment with PF-670462 or vehicle and was conducted during the
animals’ light cycle, beginning at ZT4 and ending by ZT8. The behavioral battery was scheduled
to place more stressful tests at the end of the testing period and split in to two sets of tests to
allow for the use of two different water maze tests. Additionally, each set of tests was split into
multiple smaller cohorts of mice to minimize the spread of testing time. Fear conditioning for
acute Arc expression was performed on two separate cohorts of mice. (Figure 1c) All behavioral
equipment was cleaned with 70% EtOH between mice and trials, a white noise generator was
used to reduce outside sounds from disturbing testing, and mice were allowed 30 minutes to
acclimate to the new room before all tests. Entry into any maze segment was scored when all
four paws crossed the threshold of the area.
Mice were tested in a Plexiglas fear conditioning (FC) chamber (25 x 25 cm) with metal
bar flooring within a sound attenuation chamber and recorded for all sessions. For training, mice
were placed in the chamber through a front sliding door and allowed to explore for 3 minutes
with only white noise. Mice were then presented with the conditioned stimulus (CS- 90dB tone)
for 30 seconds, co-terminating with the unconditioned stimulus (US- 2 s, 0.50 mA foot shock), 3
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and 5 minutes after the start of the test. 24 hours after training, mice were placed back into the
same context and allowed to explore for 3 minutes. One hour after the contextual text, mice were
placed in a novel context and presented with 3 minutes of white noise followed by 3 minutes of
the CS.
Mice were trained in the Morris Water Maze (MWM) for 5 days, with 4 trials per day,
with at least 30 minutes to acclimate to the room and between trials. The apparatus consisted of a
black pool with a black platform located ~2cm under the surface of the water. Four large visual
cues of different colors were mounted on white curtains surrounding the pool. For each trial, the
mouse was placed gently in the pool at a different quadrant and allowed 60 seconds to search for
the platform. Mice unable to find the platform after 60 seconds were guided to it. Mice were left
on the platform for 30 seconds before removal to a recovery cage placed on a heating pad.
Training was halted after 5 days as all groups reached an average latency to the platform of <20
seconds. Probe trials were conducted at 24 and 72 hours after the last training session. The
platform was removed, and mice placed in the quadrant opposite its previous position and
recorded for 60 seconds. No differences were found in a visible platform test, ruling out visual
deficits in either group.
The Radial arm water maze (RAWM) consisted of 6 metal arms (20 x 35 cm) in a
circular pool, with a center area 40 cm in diameter. Three removable clear Plexiglas platforms
served as escape targets for the test, seated in the end of each escape arm under ~1cm of water.
Mice were trained for 4 days, each training day consisting of 3 trials per mouse. For trial 1, all 3
platforms were in place, and the mouse was placed in the starting arm, which remained
consistent throughout all tests, and was allowed to swim for 2min or until it “escaped” by finding
one of the platforms. The mouse was allowed 30s to reference the spatial cues from the platform,
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then was removed, gently dried, and placed in a warmed holding cage for 2 minutes. For trial 2,
the process was repeated with the escape platform used in trial 1 removed, and for trial 3 only a
single escape platform remained. Errors were recorded during testing: entries into any arm that
never contained a platform were recorded as spatial memory errors and repeated entry into any
arm was recorded as a working memory error. An entry was only recorded if all 4 paws entered
the arm of the maze. Testing continued until all groups reached the final platform with an
average of <20 seconds.
The spontaneous alternation task was conducted in the Y-maze apparatus, consisting of
three arms (38 x 8 cm) connected at 120° angles from each other. Mice were placed in one arm
of the maze and allowed to explore for 8 minutes. Total entries and order of entries was
recorded.
For elevated plus maze (EPM) testing, mice were placed in the center of a raised
apparatus with two opposing open and two opposing closed arms, each (30 x 5 x 15 cm), with a
center area (5 x 5 cm), elevated 40 cm off the floor. The apparatus was well lit from above. Mice
were placed in the center and recorded for 6 minutes.
For forced swim testing (FST), mice were placed in 4L beakers containing 2.5L of water
at 27±2˚C and monitored. Swimming behavior was recorded for 6 minutes.
Motor coordination testing was performed on a Rotarod apparatus (Ugo Basile)
consisting of a 3cm diameter cylinder machined to provide a grip surface, with 5 lanes. Mice
were placed carefully onto the slow-moving rod and were tested on a ramp of 4-40rpm over 5
minutes. Latency to fall was recorded.

31

Forelimb grip strength was tested using a grip strength meter (Ugo Basile) measuring
peak force. The mouse was placed over a base plate to grasp a trapeze shaped grasping bar. This
was repeated 3 times and the peak force averaged.
Pain response was tested using a hot plate apparatus (Ugo Basile), and was essential for
ensuring there was no allodynia or hyperalgesia effects that would confound fear conditioning
results that were dependent on foot shock. We used a fixed-temperature test, heating the plate
surface to 55°C and placing the mouse in the chamber. The mouse was carefully monitored for
hind-leg flick response (or any other indicator of distress), and latency recorded.
The sucrose preference test was performed overnight during the active (dark) cycle. Mice
were singly housed with two sipper bottles, one containing 4% sucrose in water, and one
containing water. Food was placed between the bottles. Consumption from each bottle was
measured every 3 hours, and the bottle position was switched to reduce side-preference
confounds. Sucrose preference was calculated as: (sucrose solution consumption)/(total
consumption) x 100%.
Separate cohorts of mice which had not previously been exposed to the fear conditioning
apparatus were used for an acute learning paradigm to induce Arc activation. Mice were placed
in the fear conditioning chamber and presented with a series of 5 tone-shock pairings, consisting
of a 20 second tone (3000Hz) co-terminating with a foot shock (2 seconds, 0.50 mA) at 50
second intervals. Mice were placed in separate cages after testing, and tissue was collected
exactly 1 hour after the end of testing. Control mice were kept in the home cage until tissue
collection.
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Western blot
To generate a snapshot of the expression of circadian and learning and memory related
proteins at the time of behavioral testing, mice were sacrificed by rapid decapitation beginning at
ZT4 the day after a final ZT10 CK1i injection. Brains were dissected immediately to collect
hippocampus and hypothalamus, and snap frozen on dry ice. For the Arc expression experiment,
brains were dissected to collect right and left amygdala, and dorsal and ventral hippocampus.
Dorsal and ventral hippocampus were dissected by cutting at approximately bregma -4.5mm.
Western blotting was performed as published previously.[57] Tissue was lysed via
sonication in M-PER with protease and phosphatase inhibitors (10 µl/ml, Halt™ Protease and
Phosphatase Inhibitor Cocktail, Thermo Scientific Inc, Rockford, IL, USA) and centrifuged to
clear. Supernatant concentrations were detected by BCA Assay (Pierce) and adjusted. Protein
was resolved on 9% Tris-glycine polyacrylamide gels under reducing conditions and transferred
to nitrocellulose membrane (Bio-rad, Hercules CA). Membranes were blocked for 45 minutes in
5% milk in tris buffered saline containing 0.1% tween-20 solution (Boston Bioproducts,
Ashland, MA). Membranes were incubated overnight at 4 °C in specific antibodies to pERK
p44/42, GSK3β, Arg3.1(Arc) (1:1000, Cell Signaling Technology, MA, USA) PER1 (1:1000
Invitrogen, CA, USA), PER2 (1:250 Invitrogen), or BMAL1 (1:1000 Bethyl Laboratories, TX,
USA) or for 2h at RT in antibody specific to β -actin(Sigma-Aldritch, MO, USA) in tris buffered
saline with 0.1% tween20 (TBS-T) with 2% milk, washed 3 x 10 minutes in TBS-T, and
incubated for 1 hour at room temperature in horseradish peroxidase-conjugated secondary
antibody (1:7500, SouthernBiotech, AL, USA), in TBS-T with 2% milk. After washing with
TBS-T, bands were visualized with enhanced chemiluminescence (ECL; Thermo scientific)
using an image analyzer (Amersham imager 600).
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Data collection and statistical analysis
Behavioral data for MWM and Y-maze were collected using the ANYmaze program.
Spontaneous alternations in the Y-maze were calculated as (number of correct triads)/(total
number of entries-1), where a correct triad is a sequential entry into each arm without returning
to the previously visited arm. RAWM, FST, EPM, and FC were scored by hand from video
recordings by researchers blinded to the experimental conditions. FST was scored by recording
the time points during which the mouse was swimming (making forward progress in any
direction through the water) and immobile (floating with no motion, minor course correction
permitted). Total time immobile and latency to immobility were recorded. EPM was scored by
recording the time spent in each of 5 segments of the apparatus: right and left open and closed
arms, and center. FC was scored by assessing for freezing behavior of at least 2s once every 5s of
testing time. Freezing behavior was defined as no movement aside from respiration.
Western blot band intensity was quantified using Image Lab (Bio-Rad). Intensity of bands of
interest were normalized to actin band intensity. For Arc expression studies, the VEH+NL group
average was set to 1 and all data expressed as fold change from control. For other western blot
quantification, VEH group average was set to 1 and all data expressed as fold change from
control. Individual outliers falling more than two standard deviations from the group mean were
excluded.
Data were analyzed using SPSS version 25 (IBM) and are represented by mean ± SEM,
with significance assigned at p < 0.05. Levene’s test or Equality of Variances was used to
confirm homogeneity of variance within all data sets.
Training data for RAWM, MWM, and FC were analyzed using a repeated measures
ANOVA with the Geisser-Greenhouse correction. Individual outliers falling more than two
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standard deviations from the group mean were excluded, as well as one mouse with MWM
training behavior that fell outside of the confidence intervals for four out of five days of training.
Differences in single training days were calculated using unpaired t-tests.
MWM probe trials, characterization studies, and Western blots for GSK3β, PER1, PER2, and
BMAL were analyzed using two-tailed, independent samples t-tests. Welch’s t-test was used for
contextual FC and pERK expression to correct for significant Levene’s tests for variance within
groups.
Spontaneous alternation in the Y-maze was analyzed using a two-tailed, unpaired t-test,
and a Pearson’s correlation of spontaneous alternation to distance traveled and number of arm
entries was performed to ensure there were no effects of locomotion on the results.
Arc Western blots were analyzed by one-way ANOVA with Tukey post-hoc tests to compare
individual differences between groups.
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Chapter 3: Schizophrenia and cognition: introduction and literature review

Introduction
Follow up studies are necessary to determine whether the cognitive enhancement we
demonstrated used CK1 inhibition is due to an effect on the circadian rhythms of learning and
memory or another mechanism. However, CK1 inhibition or other forms of chronotherapy have
potential as a treatment options that address cognitive and circadian rhythm dysfunction in
neuropsychiatric diseases like SCZ.
While the previous chapters describe cognitive testing in the framework of a healthy
adult mouse model, the following work is focused on a disease model with cognitive and
circadian components nested within the context of a more extensive characterization. We spread
a somewhat broad net with regard to the types of behavioral characterization and the following
molecular experiments. The complexity of SCZ genetics and neurobiology, described in detail in
the following sections, demands such an approach, and significant work remains to be done to
understand the phenotype of our model
Schizophrenia
SCZ is a psychiatric disorder with a profound effect on human health, affecting nearly
1% of the population. In 1990, SCZ resulted in $33 billion in healthcare costs in the US alone[1].
Diagnosis is currently largely dependent on clinical observation of characteristic positive,
negative, and cognitive symptoms[2]. There are a number of hypotheses for the etiology of SCZ.

40

While an extensive body of research has resulted in great progress toward understanding the
disease, it has also revealed the complexity of the task.
The term “schizophrenia” was first used by Bleuler in 1950, replacing Kraepelin’s
“dementia praecox[3].” Early researchers observed deficits on cognition, memory, social
behaviors, executive function, language, and changes in personality, but were unable to identify
evidence of a brain disorder. The discovery of enlargement of the lateral ventricles via computed
tomography (CT) in 1976 was the first neuroanatomical evidence[4]. With the advent of positron
emission topography (PET) a complicated picture emerged, with many common brain
abnormalities but no unified marker to characterize all patients with SCZ. The conception of
SCZ shifted during this time: rather than a type of psychosis, it was thought of as a
neurobehavioral disorder. This conception would continue to evolve to account for different
subtypes of SCZ with diverse presentation of symptoms, and despite the general regard for
psychosis as the central feature of the disease, an increased focus on the neurocognitive aspects
has emerged[5, 6]. Current diagnosis is an exclusion process. With no pathognomonic attributes
identified, SCZ serves as a kind of umbrella term for a collection of variable symptoms that
cannot be categorized according to other disease criteria. This variability is at the core of the
problem of performing focused etiological research on the disease – it is likely that there are
multiple disease processes and causative factors involved. A summary of the basic characteristic
symptoms is presented in Table 3.1 (adapted from Carpenter et al. 1994)[7].
Patients with SCZ usually present with a subset of these symptoms. Disease presentation
can be characterized into common clinical subtypes or intermediate phenotypes. These include:
paranoid (primarily positive symptoms, including delusions or hallucinations), disorganized
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(disordered thoughts, behaviors, or speech), catatonic (abnormal movement behaviors), or
undifferentiated SCZ – a pattern of symptoms not meeting diagnostic criteria[8].

Table 3.1 Core symptoms of Schizophrenia
Category

Symptoms

Positive/ psychotic

Hallucinations (somatic, auditory, or visual), delusions

Negative

Diminished affect or emotional range, anhedonia, reduced
sociability/increased aggression, reduced sense of purpose, reduced
speech

Cognitive

Executive disfunction, disorganized thoughts, positive formal
thought disorders, impaired attention

*adapted from Carpenter et al. 1994

SCZ symptomology is often misrepresented in media, leading to the incorrect popular
belief that psychosis (and often associated violence) is the central feature of the disease[9]. In
fact, negative and cognitive symptoms persist outside of psychotic episodes, both in a prodromal
period before acute psychotic onset, and after remission of florid symptoms. Cognitive deficits
are present in 75-80% of patients with SCZ[10], and the severity of these symptoms is
associated with poorer long term patient outcome[11].
Like the heterogeneity of symptoms, the time course of symptomatic presentation and
severity is also variable. However, a general pattern emerges of sub-diagnostic symptoms during
childhood and early adulthood, presentation of an initial psychotic episode, and a pattern of
remission and re-emergence of symptoms[12]. Deterioration over time is present in a subpopulation of patients, and this timeline is subject to the effects of treatment strategies. SCZ is
widely hypothesized to be a neurodevelopmental disease, with susceptibility to genetic and
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environmental factors during perinatal period contributing the development of the disease.
Adolescence may also be a time of increased susceptibility to what are termed second-wave
“hits,” and environmental factors may continue to affect progression throughout the life of a
patient[12].
Treatment for schizophrenia
The timeline of SCZ progression and susceptibility reveals the need for relevant
biomarkers and prophylactics. Diagnosis is often delayed until the onset of psychosis, and even
with a correct diagnosis, treatment for SCZ can be challenging. This is further complicated by
divergence between help-seeking and non-adherent patient populations. Anti-psychotics have
long been considered the front line therapeutic choice, indicated at the first psychotic episode,
supported by psychosocial interventions such as cognitive behavioral therapy[13]. Efficacy of
the antipsychotic chlorpromazine, a dopamine D2 receptor antagonist, in treating positive SCZ
symptoms led to the dopamine hypothesis: the idea that patients have increased dopaminergic
mesolimbic pathway activity that leads to SCZ symptoms[14, 15]. However, this hypothesis does
not adequately address the cognitive or negative symptoms of SCZ, and treatments that only
target symptoms of psychosis may be completely useless for patients with some symptomatic
subtypes of the disease[16]. First generation antipsychotics (FGAs) (most commonly
chlorpromazine, perphenazine, and haloperidol[17]) can lead to extrapyramidal symptoms and
nonadherence. Second generation antipsychotics (SGAs), or atypical antipsychotics (most
commonly quetiapine, risperidone, aripiprazole, and olanzapine[17]) with serotonin-dopamine
antagonism were developed to attempt to overcome these issues, but also come with significant
negative side effects, and there is debate over whether they have any advantages over FGAs[18,
19].
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Furthermore, at least a third of patients with SCZ are resistant to treatment. Clozapine, an
atypical antipsychotic with weak D2 antagonism, is the current standard treatment for treatment
resistant SCZ. It has been suggested that treatment-resistant SCZ may be a biologically distinct
subtype of the disease, with studies demonstrating that treatment-resistant patients have more
pronounced cognitive deficits[20, 21], and increased polygenic risk scores[22]. Several studies
have also found associations between treatment resistance and several genes of interest,
including RELN[23].
Novel treatments in development address the idea that SCZ likely involves multiple
neurotransmitter systems that may interact with dopaminergic systems, or cause SCZ pathology
through independent mechanisms, and targeting only D2 receptors will likely be ineffective at
treating all symptoms.
Etiology of schizophrenia
The symptomatic diversity of SCZ described above is one facet of the complex problem
faced in modern SCZ research. The introduction of genetic studies offered a pathway toward
understanding what might cause the disorder, but also a new set of obstacles. While there is
extensive evidence that SCZ is highly heritable, there is also increasing evidence that it is likely
polygenic, and that disease progression and development is also be susceptible to environmental
factors[12]. There are a number of hypotheses that attempt to address SCZ etiology, but nearly
all of them include a genetic aspect. Some of the most prevalent in the literature are the:

(1) Neurodevelopmental hypothesis: the idea that the SCZ risk that arises from genetic
variants comes from their effects on brain development.
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(2) Gene-environment interaction hypothesis: originally suggested by Gottesman and
Shields[24], the idea that the impact of genetic variants interact with environmental
factors, passing a biological threshold to result in a disease state.

There is an obvious intersection here, in which the effects of genetic variants may be
neurodevelopmental, conferring the susceptibility to the environment as early as in utero.
Genetics of schizophrenia
Genome-wide association studies (GWAS), directed by the idea of “common disease –
common alleles” [25, 26] have yielded more than 100 loci associated with increased SCZ risk,
with estimates of more than 8000 single nucleotide polymorphisms (SNPs) independently
contributing to the disease[27-29], SNPs and copy number variants (CNVs) are the most wellestablished genetic risk factors, but these have only been recognized as risk rather than causal
factors. This large number of risk variants is estimated to account for only a third to a half of the
genetic risk[30]. Molecular data examined in a large study by the International Schizophrenia
Consortium evaluating common variants supports a polygenic root for SCZ that is unique from
most other psychiatric disorders, but shares considerable overlap with bipolar disease (BPD)[31].
The Schizophrenia Working Group of the Psychiatric Genomics Consortium examined up to
36,989 cases and 113,075 controls, finding consistent evidence for a polygenic risk model, and
also finding significant overlap between identified SCZ risk regions and mutations associated
with intellectual disability, major depressive disorder, and autism spectrum disorder[32]. This
genetic pleiotropy is reflected in the complicated diagnostic criteria for SCZ, and the need for
better biomarker and potentially genetic screening criteria for more specific and refined
diagnoses[33].
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The biological relevance of these genetic variants is an essential question in SCZ
research, particularly in the context of establishing novel therapeutics. Most of the identified risk
SNPs confer a low odds ratio, are in non-coding DNA regions, and cannot be easily linked to the
specific causal variant within the length of tagged DNA[28, 34, 35]. This question is at the core
of some controversy in SCZ research, as GWAS largely fail to reproduce evidence supporting
the role of many of the genes identified by “candidate gene” approaches. Disrupted-inschizophrenia-1 is a prime example – like many candidate genes, it was identified in a familial
population by a cytogenic approach[36] and has since been called into question as a risk gene,
with failure to find GWAS significance cited as explanation[37]. However, as Porteous et al.
responded to these concerns about the genetic relevance of DISC1 to SCZ, GWAS results can
lead to misleading conclusions about rare or recent genetic events, and family linkage studies
like those that have identified DISC1 in multiple populations can help us understand the
connections between common and rare variant detection to reveal relevant genes[38]. The
“common disease – common allele” hypothesis supposes a genetically homogenous disease, but
a “common disease – rare alleles” model may better address the heterogeneity of SCZ[26]. Using
this model, distinct populations may inherit different alleles with large effects. Interestingly, this
model addresses the problem of the tenacity of SCZ, which persists despite the associated
reduction in reproductive capacity that would suggest that risk alleles should undergo negative
selection[39].
Taken as a whole, GWAS and candidate gene studies consistently support a polygenic
architecture, with a substantial number of risk genes expressed in the central nervous system[40].
While the importance of genetic studies of SCZ risk cannot be ignored, an understanding
of the biological pathways involved offers a route toward finding biomarkers and developing
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more effective therapeutics. Unlike most neurodegenerative diseases, SCZ does not result in any
typical pathological hallmarks. We are still some distance from a definitive genetic description of
SCZ etiology, but there is much to be gained from understanding the biological effects of gene
variants.
Modeling schizophrenia in animals
The use of animal models to investigate the etiology of schizophrenia has been an
essential tool in developing our understanding of genetic and environmental factors related to
schizophrenia-like phenotypes. However, translation of human symptomology to animal
phenotype has important limitations that must be considered when interpreting animal data and
drawing conclusions about the human disease.
Limitations
As evident from the genetic and diagnostic complexity described here, one of the most
difficult limitations to overcome in modeling schizophrenia is the overwhelming heterogeneity
of the disease. The diagnostic criteria for the disease continue to evolve. Like many psychiatric
disorders, there are also no consistent neuropathological markers to test for schizophrenia[41].
Setting aside questions about the categorization of a broad spectrum of symptoms as a single
disease, these factors can make validation of animal models nebulous[42].
The path to developing models for schizophrenia has been laid by the extensive evidence
for the heritability of the disease. Rodent disease models are exceptionally useful for isolating
and characterizing the sequelae of single gene mutations or other factors. However, the twin and
family studies that demonstrate the heritability of schizophrenia also suggest that other factors
are at play, as there is only about 50% concordance for schizophrenia between identical
twins[43, 44]. This kind of phenotypic discordance is often attributed to environmental factors
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that occur after birth, but there is evidence to suggest that in-utero factors, epigenetic
discordance, genetic mosaicism, and stochastic factors are other potential explanations[45].
There are many theories about the etiology of schizophrenia, and there is a general
agreement in current literature that it is very unlikely to result from a single gene or
environmental factor. A large number of multi-“hit” models have emerged to address this,
examining the interaction between multiple genes, environmental factors, or combinations of
both. These attempt to address the likely complicated causes of SCZ, but like single hit models,
they carry limitations in using animals to study what is in many ways an inherently human
disease.
These difficulties in validating animal models highlight the need for clear, goal-oriented
studies. With their limitations appropriately addressed, rodent models have incredible utility in
examining multi-level relationships between causative factors, behavior, and underlying
anatomical, cellular, and molecular alterations. It is unrealistic to attempt to authenticate any
model as a complete model of schizophrenia – instead, we must choose appropriate endpoints
and corresponding assays. As Arguello and Gogos summarized in an excellent review on
modelling psychiatric disorders, we can conceptualize these endpoints as endophenotypes:
heritable and quantifiable traits that dependably reflect “discrete components of
pathophysiological processes more proximal to particular sets of predisposing genes than the
actual clinical diagnosis[41, 46].”
Behavioral assays used in models of schizophrenia
Behavioral assays are often the first level of analysis done on an animal model to
establish face validity. The types of symptoms patients with SCZ experience present unique
challenges to this type of validation. Animal correlates to many of the “positive” symptoms of
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schizophrenia are difficult to find, bearing in mind our current inability to interview a mouse to
identify the presence of hallucinations, paranoia, delusions, or changes in speech patterns.
Hyperactivity and increased sensitivity to psychotomimetic drugs are mainstays, but rely
primarily on locomotor measures[47].
Negative symptoms can be somewhat easier to quantify. The Porsolt forced swim test or
the tail suspension test are routinely used to evaluate depression. Sucrose-preference can be used
to evaluate depression-like behavior, but reductions in sucrose preference can also indicate
neophobia or anhedonia[48]. Elevated plus maze, the open field test and light-dark box are
commonly used for anxiety-like behavior[49]. Social interaction tests are also more directly
analogous to measures in humans, and can measure social withdrawal, aggression, social
memory, and preference for social novelty[47].
There are many more options for cognitive testing, which can identify deficits in various
types of memory, attention, and executive function, though some attributes of cognitive deficits
such as disordered thinking are much more difficult to assay in rodents. Working memory and
sensorimotor deficits are common in patients with SCZ. Working memory is commonly assayed
in the radial arm water maze (RAWM) and spontaneous alternation task in the Ymaze or
Tmaze[50]. Poor performance on tasks can reflect working memory deficits, but can also be due
to other SCZ-relevant cognitive impairments such as a lack of cognitive flexibility or
perseveration[47, 51]. Sensorimotor gating is commonly assayed by prepulse inhibition, a
measure analogous in rodents and humans, and is translatable to the ability to appropriately filter
sensory information. Many learning and memory assays exist, including the water mazes, Barnes
maze, classical fear conditioning, and operant conditioning. Latent inhibition and attentional set-
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shifting tests can be used to assay attention. (See Powell et al. 2014 for a detailed review of
behavioral measures[47])
Due to the intricacy of SCZ symptomology, and the many factors involved in interpreting
animal behavior, the use of multiple behavioral tests to assay each kind of behavior are useful for
confirming aspects of a model’s phenotype.
Disrupted-in-schizophrenia-1
The model we investigate in the following chapter combines two individual genetic
mutations associated with schizophrenia. The first of these is the forebrain-inducible mutant
human disrupted-in-schizophrenia-1 (DISC1) model developed by Pletnikov’s group at John’s
Hopkin’s University. A Tet-off double transgenic system (Clontech, Palo Alto, CA, USA) was
used to generate the model, allowing temporal control of mutant human DISC1 expression[52].
While we allowed mutant human DISC1 to be constitutively expressed during both development
and adulthood for these studies, using the Tet-off system to temporally restrict expression will be
a useful tool to understand the contribution of Reelin and DISC1 to the changes we see in our
gene-gene interaction model, or to susceptibility to the development of psychiatric-like
behaviors.
DISC1 was discovered in 1970 via a cytogenic approach by a group from the University
of Edinburgh in a large Scottish pedigree, in which 34 of 77 members of a family carried a
balanced translocation t(1:11) (q43,q21) disrupting the gene now termed DISC1. Of these 34
family members, 16 were diagnosed with psychiatric illnesses including schizophrenia,
schizoaffective disorder, and major depression[53]. DISC1 has since been associated with
schizophrenia and other psychiatric disorders in a number of other populations, including distinct
Finnish[54], Chinese[55], and Japanese[56] populations.
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The DISC1 protein
The DISC1 gene encodes a large 854 amino acid protein with an N-terminal head and
helical C-terminal domain, structurally similar to myosins and other proteins involved in
intracellular transport, synaptogenesis and function, and microtubule binding[57, 58]. DISC1 has
multiple subcellular locations and functions[59, 60], and has been described as a hub protein,
producing pleiotropic effects through interactions with multiple other proteins[61]. DISC1 can
both form multimers, and self-aggregate to form detergent-insoluble aggresomes, which have
been detected in some human postmortem SCZ brain tissue[62, 63].
Spatial and temporal expression of the DISC1 protein is complex, and detection is
complicated by truncated and post-translationally modified variants[64]. DISC1 expression is
consistently described in the forebrain in both development and adulthood[65-67]. It is expressed
widely in the mouse brain, including cortex, hippocampus, hypothalamus, and cerebellum[68].
Its expression is developmentally regulated, and has peaks in expression that correlate
temporally with active neurogenesis[69].
DISC1 binding partners and roles
DISC1 has an extensive interactome of binding partners with diverse roles, including
neuronal migration, neurite outgrowth, and synaptic plasticity.
Of particular interest are DISC1 interactions with proteins that bind to microtubule
transport complexes. Kinesin and dynein, molecular motors essential for neuronal intracellular
trafficking, both interact with DISC1. NudE-like (NUDEL) and lissencephaly-1 (LIS1) are
DISC1 binding partners that regulate dynein activity[67, 70, 71], and form a complex that is
essential for axon elongation. DISC1 serves as a cargo protein, linking Kinesin-1 to the NUDELLIS1 complex and regulating its transport to axons[72].
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The exact pathological mechanism of the DISC1 chromosomal translocation has yet to be
determined. The major hypotheses for loss-of-function include haploinsufficiency, formation of a
fusion protein, or formation of a C-terminal truncated DISC1 protein[73]. The DISC1 model
used for these studies was developed to address the third idea. C-terminal truncated human
DISC1 interacts with full-length DISC1, exerting dominant-negative effects[74], and interrupts
the formation of protein complexes. C-Terminal truncation specifically removes the region of
DISC1 necessary for interaction with NUDEL, and prevents formation of the DISC1-NUDELLIS1 complex[52, 67], leading to disrupted neuronal migration and neurite outgrowth in the
cortex[75]. Mouse models of C-terminal truncated DISC1 have demonstrated reduced dendritic
length and spine density in hippocampal dentate granule cells[76] and cultured hippocampal
neurons[77].
Lissencephaly, a disease of severely disrupted neuronal migration, can be caused by LIS1
mutations[78], and disruptions in the DISC1-NUDEL-LIS1 complex have been implicated. LIS1
provides a potential point of interaction between DISC1 and reelin, as it binds to phosphorylated
Disabled-1 (DAB1), as essential component of the reelin signaling pathway. LIS1 is also a
regulatory subunit in the platelet activating factor (PAF) acetyl hydrolase 1b (Pafah1b) protein
complex, which binds to the reelin receptor VLDLR[79].
DISC1 in adult neurogenesis
Divergent spatial and temporal roles are a fascinating attribute of DISC1 function. DISC1
is an essential regulator or neuronal migration during development, facilitating cortical
neurogenesis and dendritic outgrowth[80]. It also negatively regulates the migration and
dendritic outgrowth of adult-born neurons in the hippocampus and modulates the tempo of
synaptic integration, possibly through its interaction with NUDEL1[81]. In the adult
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hippocampus, DISC1 may serve as a “brake” for neuronal migration[82]. Various mouse models
for DISC1 disruption have demonstrated different effects on various aspects of adult
neurogenesis. Changes to DISC1 structure have been shown to alter its ability to bind to its
partners, and affect different downstream pathways[83]. Models that disrupt N-terminal
interactions of DISC1 interrupt binding to Glycogen synthase kinase 3 beta (GSK3β) lead to
reduced cell proliferation during development
Reelin
The other piece of our gene-gene interaction model is reelin haploinsufficiency. The
heterozygous reeler mouse (HRM) expresses 50% of the normal amount of reelin, and unlike
mice with the homozygous recessive Reeler mutation, they are grossly normal with a subtle
behavioral phenotype.
The reeler mouse was first identified in 1951 [84], characterized by a pronounced ataxia,
dystonia, tremor, and hypotonia[85, 86]. It was used as a model of abnormal corticogenesis for
nearly fifty years before the RELN gene was identified and cloned, and its protein product named
reelin[87, 88]. Mouse and human RELN are highly homologous, respectively located at 7q22.1
and chromosome 5[87, 89]. The homozygous RELN mutation causes abnormal layering of
migrating neurons, most pronounced in laminated brain structures including the cortex,
cerebellum, and hippocampus[86, 90].
The reelin protein
Reelin is a large (388kda) secreted extracellular matrix glycoprotein with multiple unique
roles in development and adulthood[91]. Structurally, reelin consists of eight epidermal growthfactor (EGF) like repeats, and is cleaved to generate N-terminal, C-terminal, and central
fragments[92]. The reelin signal transduction pathway (reviewed expertly by Herz & Chen [93])

53

initiates with binding to VLDLR and apolipoprotein E receptor 2 (ApoER2)[94], causing
receptor clustering and interaction with the intracellular adaptor protein Disabled-1 (Dab-1).[93]
Receptor clustering recruits SRC family tyrosine kinases (SFKs), inducing feed-forward
activation of Dab-1 and initiates a cytosolic kinase cascade[95]. Downstream, GSK3β is
inhibited, reducing Tau phosphorylation and increasing microtubule stability. Several other
downstream targets of this pathway are involved in the regulation of microtubule dynamics and
actin cytoskeleton rearrangement. Crucially, ApoER2 associates with the scaffolding protein
postsynaptic density protein 95 (PSD-95), coupling the signaling complex to the NMDA (Nmethyl-D-aspartate) receptor (NMDAR), and allowing SFK tyrosine phosphorylation of the
receptor, increasing Ca2+ influx and activation of the transcription factor cyclic AMP-response
element binding protein (CREB)[93]. The reelin pathway also interacts with the lissencephaly 1
(LIS1) complex, which is involved in neuronal migration[96]. These signaling pathways provide
a physiological mechanism for reelin’s diverse roles in both development and adulthood.
Reelin in development and adulthood
During embryonic development, reelin is secreted from Cajal-Retzius cells in the
marginal zone of the cerebral cortex to guide the radial migration of excitatory neurons and
enable proper “inside-out” cortical lamination[97, 98]. This is likely achieved by graded
distribution of reelin across the cortex, where it attracts migrating neurons then serves as a stop
signal[98]. Reelin signaling is also involved in neuronal migration and development of foliated
structures in subcortical brain areas, including the hippocampus and cerebellum.
In the adult brain, reelin expression pattern changes, shifting from Cajal-Retzius neurons
to GABA(γ-aminobutyric acid)-ergic interneurons in the cortex and in the hippocampus[99].
Reelin is involved in regulating migration, dendritic maturation, synaptogenesis of adult-born
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neurons in the adult hippocampus[100]. Reelin is also a modulator of synaptic plasticity and
learning in the adult[101]. Knocking out reelin or either of its receptors disrupts hippocampal
long-term potentiation (LTP) and leads to deficits in learning and memory behavioral testing,
while supplementing reelin produces a robust increase in LTP[93, 101]. However, recent work
using an inducible reelin knockout model have demonstrated intact learning and memory when
reelin was knocked out in the adult, which suggests that the phenotypes of heterozygous and
homozygous reelin knockout mice may be largely due to developmental effects[102].
Reelin in neurodevelopmental disorders and the heterozygous reeler mouse
A reduction in reelin expression (or that of its cleavage products) has been noted in
multiple neuropsychiatric disorders, including SCZ, ASD, and BPD. (Table 3.2, adapted from
Folsom et al, 2012[91]) The disrupted cytoarchitecture and severe behavioral deficits in reeler
mice make them difficult subjects for translational studies. However, the ~50% reduction in
reelin expression in the HRM[103] coupled with the absence of major phenotypic abnormalities
makes this an attractive and extensively studied model.
The contribution of reduced reelin expression in these disorders is not clear, nor is there an
established causal relationship. It is possible that the reduction in expression is a symptom RELN gene regulation can be linked to SCZ. The RELN promotor is likely under epigenetic
control[104, 105], and along with the glutamic acid decarboxylase 67 (GAD67) promoter, is
downregulated by methylating enzyme DNA methyltransferase 1 (Dnmt1)[106]. Studies of
postmortem brains from SCZ patients revealed hypermethylation of RELN promotor CpG
islands, increased Dnmt1, and downregulation of RELN and GAD67 gene expression[107-110].
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Table 3.2 Reelin expression in selected neuropsychiatric disorders
Disorder

Effect and brain area

Reference

Schizophrenia

Reduced mRNA expression in prefrontal cortex

[107, 111,
112]

Reduced mRNA expression and immunoreactivity in

[111, 113]

hippocampus

Autism

Reduced expression of Reelin 180 kDa in cerebella

[114]

Reduced mRNA expression in prefrontal cortex

[112]

Reduced expression of Reelin 180 kDa in frontal cortex and

[115, 116]

cerebellum
Reduced expression of Reelin 410 kDa in frontal cortex and

[116]

cerebellum
Bipolar

Reduced expression of Reelin 410 kDa and 180 kDa in

disorder

cerebellum
Reduced Reelin immunoreactivity in hippocampus

[114]

[113]

*adapted from Folsom et al, 2012

Reelin insufficiency fits plausibly into the neurodevelopmental hypothesis of SCZ –
neuronal positioning errors resulting from microtubule dysfunction may contribute to a “first-hit”
in SCZ development, and these same pathways are later involved in synaptic plasticity[117].
Reelin’s role in NMDA receptor function in GABA-ergic interneurons also supports this idea.
Dysregulation of inhibitory/excitatory balance has been posited as a contributing factor in SCZ,
and reelin reduction has been shown to impair inhibitory signaling in the hippocampus[118].
Reelin insufficiency alone can therefore potentially produce two individual temporal “hits” that
may contribute to SCZ. Additionally, reelin is an attractive candidate for study, as exogenous
reelin supplementation has shown promising results in rescuing deficits present in models of
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reelin insufficiency[119-121], and may offer a new route for potential SCZ therapeutics that is
sorely needed.
While several aspects of the HRM lend credence to its usefulness as a potential SCZ
model, attempts to recapitulate human SCZ-relevant behaviors using rodent behavioral testing
have met with mixed results. In fact, several studies with extensive behavioral batteries have
concluded either partially or in full that the HRM is not a useful model for SCZ relevant
behaviors[122-124]. The utility of the HRM as a model, and indeed the behavioral phenotype
itself, is still subject to some controversy, marked by opposing behavioral results emerging from
different laboratories. The nature of this disagreement likely stems from a combination of
factors: differences in methodology between laboratories, and more importantly the nature of the
types of relevant behaviors. The nature of neuropsychiatric symptoms in humans presents a
significant challenge to measure meaningfully in an animal model[125, 126]. Some of the most
relevant findings include age-dependent alterations in startle response and sensorimotor gating
with partial similarities to SCZ [127], changes in emotionality and decreased inhibition [128],
deficient performance in operant conditioning tasks[123], and decreased contextual fear
conditioning learning[124]. Some of these extensive behavioral phenotyping studies have found
few differences between the HRM and wild-type (WT) littermates in behavioral assays related to
anxiety, affect, activity, social aggression, locomotion, nociception, spatial learning, and working
memory.
The neuroanatomical abnormalities in the HRM may offer a more convincing argument
for its utility as a model for understanding susceptibility to SCZ. The HRM shares a number of
morphological changes common to SCZ patients, including altered dopaminergic markers in the
mesotelencephalic dopamine pathway[129], a reduction in cortical thickness, reduced dendritic
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spine density in the prefrontal cortex and hippocampus, and fewer GAD67 positive neurons in
the prefrontal cortex[103].
Gene-environment interactions
While there is little argument that the etiology of SCZ has a strong component of
heritability likely arising from multiple genetic factors, human and animal studies support a
diathesis-stress model of schizophrenia, in which the disease state is ultimately a result of
environmental factors experienced by an individual with genetic vulnerability.
While reelin expression seems linked to SCZ, the nature of the relationship remains
unclear, and haploinsufficiency alone seems unlikely to provide an inclusive model for the
disease. This is unsurprising, given the heterogenous genetics and symptomatic presentation of
SCZ. In response to this idea, several studies have combined reelin haploinsufficiency with
various environmental insults to general gene-environment interaction models and ask how
reelin insufficiency might contribute to SCZ susceptibility.
DISC1 and HRM gene-environment studies have both used environmental factors
including stress, maternal separation, social isolation, and immune challenges, with variation in
timing with respect to critical windows of susceptibility to neuropsychiatric disease
development. A complete review of these results is somewhat out of the scope of this thesis.
Cash-Padgett et al. 2013[130] reviewed the many gene-environment interaction models for
DISC1, and HRM was reviewed by Laviola et al, 2009[131], who argues that a key facet of the
HRM phenotype is in fact a dampened responsiveness to environmental challenges, and overall
poor cognitive flexibility[132, 133]. Future studies with the HRM/DISC1 model will likely
involve determining whether the genetic load of both mutations confers increased susceptibility
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to the development of a behavioral and neuroanatomical phenotype translatable to SCZ in
humans.
The nature of the HRM/DISC1 model as an interaction model is essential consideration
for the selection and interpretation of measures. While a genetic or environmental factor might
be expected to predict worse outcomes, the combination may in fact have either protective or
adverse effects, or entirely unexpected sequelae[134, 135]. Study design should be able to detect
bidirectional effects and avoid myopic selection of outcome measures related only narrowly to
the expected results.
The goal of any animal model is to fulfill as many criteria for validity as possible. This
should include face validity (observable and translatable behavioral or biological outcome
measures that match the human disease), construct validity (matching relationships between
causative factors and disease states or phenotypes), and predictive validity (the ability of the
model to predict effects of treatments analogous to those in humans) for the disorder of
interest[136]. This work establishes partial face and construct validity of the HRM/DISC1
model, finding alterations in some SCZ-relevant behavioral tests that are translatable to human
symptomology, and neurobiological pathology thought to be relevant to SCZ. Future work will
attempt to determine the predictive validity of the model.
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Chapter 4: Alterations in cognition, inhibition, and neurogenesis in a novel schizophrenia
model using disrupted-in-schizophrenia-1 and reelin gene mutations
Mahoney H., Bloom, C., Justin H, Gonzalez D, Valladares, A., OCampo, A., Morris,
C., Carter, B., Peterson, E., Faulkner J., Reiss, S., Capraro B., Peterson E, Walker
Z., Lussier, A., Gamsby J, Weeber EJ, Gulick D.

Abstract
As described previously, the etiology of schizophrenia (SCZ) is multifactorial and highly
individual. In this study, we evaluated a novel transgenic mouse model in which two putative
SCZ susceptibility genes, Disrupted-in-schizophrenia-1 (DISC1) and reelin (RELN), were
disrupted. We hypothesized that combined genetic disruption would result in a more severe SCZlike behavioral phenotype than either disruption alone, and that alterations in inhibitory neuronal
signaling and neurogenesis would underlie this phenotype. Many of the expected molecular
changes were present, and the model recapitulates several hallmark behaviors used in rodent
studies to model human SCZ symptoms. However, the behavioral phenotype is clearly not
simply additive of the characteristics of the two single mutations. We found alterations in
mobility or anxiety-type behavior, subtle alterations in circadian rhythms, and a more elusive
cognitive deficit than expected.
Heterozygous, haploinsufficient reelin mice were bred with mice expressing dominantnegative c-terminal truncated human DISC1 to produce offspring with both mutations.
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Compared to wild-type controls, these mice had reduced pre-pulse inhibition, indicating a
sensorimotor gating deficit. Transgenic mice also exhibited increased freezing and immobility in
several behavioral tests. Diazepam failed to rescue anxiety-like behaviors, paradoxically
increasing activity in the transgenic mice. We found increased α1-subunit containing GABA
receptor expression in the prefrontal cortex, and a reduction in the population of fast-spiking
parvalbumin positive neurons. Maturation of adult-born neurons in the hippocampus was also
altered in HRM/DISC1 mice. While there was no difference in the total number proliferating
cells, or adult-born immature neurons, more of these cells were in immature stages of
development and the rate of survival was increased.
To our knowledge, this is the first study in which homozygous DISC1 mutation has been
combined with RELN haploinsufficiency. We found that this combination produced a phenotype
that is relevant to some aspects of neuropsychiatric diseases like SCZ. Further studies will focus
on expanding our understanding of the changes in circadian rhythms, adult neurogenesis, and
inhibitory signaling. In the future, this model will be used to investigate gene-environment
interactions that may lead to SCZ susceptibility.

Keywords: Schizophrenia, Reelin, Disrupted-in-schizophrenia-1, adult neurogenesis, GABA,
animal behavior, learning and memory, hippocampus, prefrontal cortex

Introduction
Schizophrenia (SCZ) is a devastating psychiatric disorder, with an estimated economic
burden of $155.7 billion in the US[1]. It affects 1% of the population directly, and it has a farreaching impact on family, community, and caregivers. SCZ is characterized by positive
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(hallucinations), negative (impaired social abilities, reduced affect), and cognitive symptoms[2].
The disease usually manifests in early adulthood and is thought to be a neurodevelopmental
disorder resulting from a combination of genetic and environmental effects. Alterations in
cognitive function in SCZ include impairments in working memory[3]. Underlying pathology
includes alterations in the GABA (γ-aminobutyric acid) system, including decreased GAD67 (67
kilodalton isoform of glutamic acid decarboxylase) particularly in parvalbumin-expressing
inhibitory GABAergic neurons in the dorsolateral prefrontal cortex[4]. Reductions in gray
matter, and reduced dendritic spine density and dendrite arborization is also consistently
observed[5]. SCZ is highly heritable; twin and family studies demonstrating 60 – 90% disease
liability due to genetic factors[6].
Current treatment strategies for SCZ focus primarily on treating symptoms with
antipsychotic drugs, sometimes in conjunction with psychosocial treatment. While positive
symptoms can be responsive to drug therapy, many patients demonstrate a treatment-resistant
form of SCZ, and negative symptoms such as deficits in cognitive function and social interaction
show little improvement on these medications. In addition, treatment non-adherence remains a
serious obstacle due to patient dissatisfaction with current treatment options, due either to
undesirable side effects or modest symptomatic relief[7]. One reason for poor treatment efficacy
is that neuroanatomical and neurotransmitter abnormalities exist before the onset of psychosis,
suggesting that symptom-based treatment may be of limited efficacy in brains already altered by
the disease pathology[8-10]. There is currently no method for the treatment or prevention of
cognitive dysfunction in schizophrenia patients, despite evidence that it more negatively impacts
outcomes than psychosis[4, 11]. Although many genetic models of schizophrenia have been
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proposed, drug discovery has focused on reducing symptoms of psychosis, with some secondgeneration antipsychotics attempting to address negative symptoms with limited efficacy[12].
Here we evaluate the validity of a novel gene-gene interaction mouse model of SCZ. We
used mice with mutations in two genes associated with schizophrenia, DISC1 and RELN. DISC1
encodes the protein Disrupted-in-Schizophrenia-1 (DISC1), the truncation of which has been
linked to SCZ in multiple studies[13]. The DISC1 protein functions as a scaffold, complexing
with other neurodevelopmental proteins to enable signal transduction and neurite outgrowth[14,
15]. DISC1 is highly expressed in the forebrain during development, corresponding both with
RELN’s expression pattern and the timeline of SCZ susceptibility. DISC1 transgenic mice
express a truncated human DISC1 gene under the control of tetracycline-controlled transactivator
(tTa) driven by the Calcium/Calmodulin Dependent Protein Kinase II Alpha (CAMKIIα)
promotor, which localizes the expression of the mutant DISC1 protein to the forebrain.
Expression is not found in astrocytes or microglia, and is localized to neurons in the olfactory
bulbs, frontal cortex, hippocampal pyramidal cells, and hippocampal granule cells[13].
We bred DISC1/tTa mice with mice with RELN haploinsufficiency, termed the
heterozygous reeler mouse (HRM). The large secreted extracellular matrix glycoprotein reelin,
encoded by the RELN gene, has essential roles in both development and adulthood. Human SCZ
brains have reduced reelin expression in multiple areas, including the hippocampus and
prefrontal cortex[16-18]. Variations in RELN have been positively associated as a risk factor for
SCZ[19, 20], and are also a risk factor when combined with variations of other genes such as
brain-derived neurotrophic factor[21]. During development, the reelin protein is secreted by
Cajal-Retzius cells in the cortex and hippocampus, and is essential for proper neuronal
migration, as well as dendritogenesis [22, 23]. In adults, reelin is expressed by somatostatin
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expressing neurons, as well as a fraction of parvalbumin-expressing GABAergic interneurons in
the cortex and hippocampus, which are reactive to prenatal immune activation and adolescent
stress[24]. The ability of environmental insults during development to affect reelin-expressing
cells in the adult make reelin an attractive candidate for studying a developmental disorder like
SCZ. Reelin is involved in the modulation of learning and memory, synaptic plasticity, and
neurogenesis in the adult brain[25, 26].
Reelin expression is reduced by approximately 50% in the heterozygous reeler mouse
(HRM), similar in magnitude to the reduction seen in the postmortem psychotic brain[16]. These
mice have subtle deficits in prepulse inhibition, cognition, and executive function; reduced
GAD67; reduced dendritic spine density and arborization in the cortex and hippocampus; and
deficits in long-term potentiation (LTP)[27].
Reelin and Disc1 share molecular pathways involved in regulation of neurogenesis and
neuronal migration. Their signaling pathways converge on the serine-threonine kinase glycogen
synthase kinase 3β (GSK3β), which is phosphorylated and inhibited, disinhibiting downstream
gene expression to increase neurogenesis, synaptogenesis, neuron growth and survival[28, 29].
The Disc1 protein complexes with lissencephaly 1 protein (LIS1) and nuclear element
distribution like protein (NUDEL), and is also thought to interact with reelin receptors and
downstream effectors, likely influencing neuronal migration[30-32]. (Figure 4.1)
We crossed mice from HRM, DISC1, and Camk2a-tTa tet-off lines to produce
HRM/DISC1 mice, an inducible triple transgenic model of impaired neurogenesis and
neuropsychiatric disease. We subjected these mice to behavioral testing and
immunohistochemical evaluation, hypothesizing that combined disruption of DISC1 and RELN
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Figure 4.1: Reelin and Disc1 signaling pathway interactions. Schematic showing simplified
reelin and Disc1 pathway interactions influencing neurogenesis and neuronal migration. Disc1
and reelin pathways converge on inhibition of glycogen synthase kinase 3β (GSK3β). Reelin
binds to its receptors very low density lipoprotein receptor (VLDLR) and apolipoprotein E
receptor 2 (ApoER2)[33], causing receptor clustering and interaction with the intracellular
adaptor protein Disabled-1 (Dab-1)[34]. Receptor clustering recruits SRC family tyrosine
kinases (SFKs), inducing feed-forward activation of Dab1 and initiates a cytosolic kinase
cascade[35]. Dab-1 phosphorylation activates phosphoinositide 3-kinase (PI3K) and leads to
activation of protein kinase b (PKB), ultimately inhibiting GSK3β. This reduces Tau
phosphorylation, increasing microtubule stability. Disc1 also inhibits GSK3β through its Nterminal domain. Inhibition of GSK3β by reelin signaling and Disc1 leads to activation of
transcription factors involved in neural progenitor proliferation and regulation. Reelin receptor
ApoER2 also associates with the scaffolding protein postsynaptic density protein 95 (PSD-95),
coupling the signaling complex to the NMDA (N-methyl-D-aspartate) receptor (NMDAR)[34].
NMDAR signaling likely either mediates DISC1 expression, or Disc1 acts downstream of
NMDAR signaling to regulate neuronal migration[29]. Disc1 acts as a scaffolding protein,
interacting with lissencephaly 1 (LIS1) and Nuclear distribution protein nudE-like 1 (NUDEL) to
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form a developmentally regulated complex which is involved in neuronal migration[36, 37].
Reelin also interacts with LIS1 via its effector protein Dab1, possibly through sequential
activation, to regulate CNS lamination[38].

expression would result in a more severe SCZ-like phenotype than either mutation alone,
including behavioral and learning deficits, and altered neurogenesis characterized by aberrant
maturation of adult-born neurons in the hippocampus. Confirming face validity of the
HRM/DISC1 model for SCZ will allow investigation of these common molecular pathways,
potentially yielding new targets for the treatment.
Results
Our first goal was to generate a general behavioral profile of HRM/DISC1 mice, both to
determine whether they display SCZ-associated phenotypes, and to ensure that there were no
gross behavioral abnormalities that might confound interpretation of other behavioral results. It
is essential not only to investigate how this phenotype compares to wild-type (WT) controls, but
also categorize differences between this new gene-gene interaction model and the single
mutation HRM and mutant human DISC1 models that have already been well characterized. To
this end, we performed our behavioral tests on adult male mice, 2-6 months of age, in four
groups: WT, HRM, DISC1, and HRM/DISC1.
Altered activity, thigmotaxis, and prepulse inhibition in HRM/DISC1 mice
We chose a battery of behavioral tests including measures translatable to human SCZ
characteristics, and well as measures designed to generate a general characterization of the
model. We first ensured that all groups were capable of normal and equivalent locomotion and
nociception. We used latency to fall in a three-trial Rotarod test as a measure of locomotor
coordination. A repeated measures ANOVA was significant for trial (F(2,30)=15.365 p<0.001),
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but there was no interaction between trial and genotype (F(6,30)=0.705 p=0.648), indicating that
all groups improved performance comparatively over the three trials (Figure 4.2a). Despite this,
there is an alteration in mobility evident across several other tests. We noted no weight
differences between adult mice of any group (F(3,33)=1.167, p=0.339, one-way ANOVA).
(Figure 4.2b) Nociception also appeared normal, as we found no differences in latency to hind
leg lift in a hot plate test (Welch’s ANOVA, F(3,18)=2.256, p=0.090). Despite the lack of
statistical significance, the effect size in the hot plate test was relatively large (Cohen’s f=0.7229)
and potential differences in nociception cannot be eliminated as a possibility. (Figure 4.2d)
We examined immobility in the open field (OF) and found group differences using
Welch’s ANOVA (F(3,14.449)=4.221, p=0.025) to account for significant differences in
variability between groups (Levene’s F(3, 28)=6.670, p=0.002). (Figure 4.2c) While the
HRM/DISC1 group were on average immobile nearly a minute longer (mean difference: 59.13s)
than WT mice, this difference was not significant (p=0.242, Games-Howell correction) but the
effect size was large (Cohen’s f=0.5898). DISC1 mice performed similarly to WT (p=0.635), and
HRM mice spent more time immobile (p=0.023). We also compared time spent exploring the
center of the OF as a measure of exploratory behavior. A one-way ANOVA revealed significant
group differences (F(3,28)=4.112 p=0.015), driven by a reduction of time spent in the center by
HRM/DISC1 mice compared to any other group (p=0.002 vs WT, p=0.028 vs HRM, p=0.041 vs
DISC1, Fisher’s LSD post-hoc). The reduction in time spent in the center indicates increased
thigmotaxis, which is considered an index of anxiety-like behavior in mice[39]. Noting a pattern
of activity in the apparatus, we followed up on this by comparing time spent in the corners,
finding an even more pronounced difference between HRM/DISC1 mice and WT or single
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Figure 4.2: Altered activity, thigmotaxis, and prepulse inhibition in HRM/DISC1 mice (a)
Latency (s) to fall from rotarod with 4m/s acceleration ramp. Trials were administered on the
same day, approximately 30m apart. (n=3-7) (b) Weight (g) of 5-6 month old mice (WT n=13,
HRM n=6, DISC1 n=4, HRM/DISC1 n=11) (c) Open field: Times (s) immobile in any part of
the apparatus, time in the center, and time in the corners. (n=7-8) (d) Latency (s) to hind leg lift
or flick on a fixed 55◦C hot plate (n=3-6) (e) Startle response measured as maximum velocity
(vMAX) in response to a 120dB white noise pulse with no prepulse. (n=6-10) (f) Pre-pulse
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inhibition, measured as percent reduction in startle response compared to mean 120dB vMAX
when presented with a prepulse 100ms before main 120dB pulse. (n=6-10) Outliers removed by
individual data points falling greater than 2 standard deviations from the mean. Data represented
as mean ± SEM.

mutant groups (F(3,28)=8.871 p<0.001, one-way ANOVA) (p<0.001 vs WT, p>0.001 vs HRM,
p=0.001 vs DISC1, Fisher’s LSD post-hoc). (Figure 4.2c)
We next tested pre-pulse inhibition, a measure translatable to sensory gating deficits in
human SCZ patients. While there was an effect of decibel level (F(4,60)=9.985, p=<0.000) but
no interaction between decibel level and genotype (F(12,60)=0.649, p=0.138) in a repeated
measures ANOVA, we found differences in pre-pulse inhibition in response to the 82dB
(F(3,25)=6.664, p=0.002, one-way ANOVA) and 86dB (F(3,25)=7.122, p=0.001, one-way
ANOVA) pre-pulses. Following the 82dB prepulse, inhibition of the startle response was
significantly lower in all groups compared to WT (p=0.031 vs HRM, p<0.001 vs DISC1,
p=0.003 vs HRM/DISC1), Fisher’s LSD post-hoc). Following the 86dB prepulse, inhibition of
the startle response was lower in HRM/DISC1 mice compared to WT (p=0.001), and HRM
(p=0.003). Inhibition was also lower in DISC1 mice compared to WT (p=0.005), and HRM
(p=0.028). (Figure 4.2f)
Interestingly, we also found differences in startle response to the 120dB standalone pulse
(Welch ANOVA: F(3,10.916)=5.183, p=0.018) due to a reduction in startle response by
HRM/DISC1 compared to DISC1 mice (p=0.017, Games-Howell correction). (Fig 4.2e)
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HRM/DISC1 mice have altered circadian rhythms
To determine whether HRM/DISC1 have altered circadian rhythms, a common comorbidity in neuropsychiatric patients, we used individual activity monitoring cages with
controlled lighting. We measured the length of the circadian period (Tau) in standard 12-12
light-dark conditions, confirming that all groups are about to entrain to a typical 24 hour period
with lighting cues (F(3,13.159)=0.573, p=0.643, Welch’s ANOVA). (Figure 4.3a) We also found
no differences in the length of the endogenous free-running period, measured in constant
darkness (F(3,29)=0.445, p=0.723, Welch’s ANOVA). However, there appear to be potential
differences in the free-running period, reflected by a modest effect size (Cohen’s f=0.3282). We
next tested the ability of the circadian period to adapt to a 5-hour phase advance, in which the
lights-on and lights-off times were each moved 5 hours earlier in the day. During the phase
advance, the average period length during the 6-day transition varied between groups
(F(3,18)=4.677, p=0.017, Welch’s ANOVA). We used Games-Howell post-hoc testing to
determine individual differences, and found that the average HRM/DISC1 Tau was more than 30
minutes longer than WT Tau (p=0.002), about 20 minutes longer than HRM Tau (p=0.049), but
similar to DISC1 Tau (p=0.224), suggesting that the circadian rhythms of HRM/DISC1 mice
may adapt differently to changes in lighting conditions. (Figure 4.3a)
We also examined bouts of activity per day in the running wheels in each condition. In
LD, group differences (F(3,15)=4.152, p=0.031, one-way ANOVA) were driven by a decrease in
HRM/DISC1 bouts compared to WT (p=0.049) and HRM (p=0.006). In DD, we found a similar
pattern in group differences (F(3,14)=3.986, p=0.038, one-way ANOVA) due to the decrease in
in HRM/DISC1 bouts compared to WT (p=0.020) and HRM (p=0.010). We found no differences
in bouts during the phase shift. (Figure 4.3b)
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Figure 4.3: Abnormal period length and bouts of activity in the circadian rhythms of
HRM/DISC1 mice (a) Length (h) of circadian period in 12-12h light-dark (LD, standard) lighting
conditions, 24h dark (DD), and during a 5 hour phase-advance (shift). Note y-axis does not begin
at zero. (n=5-7) (b) Number of bouts of wheel-running activity during LD, DD, and shift lighting
conditions. (WT n=4, HRM n=4, DISC1 n=2, HRM/DISC1 n=6) (c) Relative amplitude of daily
rhythms, calculated as the difference between M10 and L5, normalized by their sum. (n=7-10)
(d) Interdaily stability. Values closer to 0 indicate gaussian noise, values closer to 1 indicate
stronger daily rhythms. (n=7-10) (e) Intradaily variability. Values closer to 0 indicate reduced
fragmentation of rhythms, values closer to 2 indicate gaussian noise. (n=7-10) Data falling more
than 1.5 standard deviations from the mean were excluded. Data represent mean ± SEM
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In LD, we found no differences in relative amplitude (RA) a measure of the strength of
24-hour rest-activity rhythms (F(3,12.951)=3.117, p=0.063, Welch’s ANOVA), interdaily
stability (IS), a measure of the invariability of rhythms between days (F(3,14.49)=3.117,
p=0.265, Welch’s ANOVA), and intradaily variability (IV) which measures fragmentation of the
sleep-wake cycle and is higher in subjects that nap during their active cycle and are awake more
often at night (F(3,19)=1.392, p=0.281). (Figure 4.3c-e)
HRM/DISC1 mice display normal affective behaviors but reduced preference for
social novelty
We next evaluated affect and sociability. To detect depression-like behavior, we used the
Porsolt forced swim test, measuring latency to immobility and total time immobile. Repeated
measure ANOVAs with the Greenhouse-Geisser correction showed a significant reduction in the
latency to immobility between Day 1 and Day 2 of the test (F(1,41)=76.984, p<0.001), but
latency to immobility did not differ significantly between groups (F(3,41)=1.022, p=0.394).
(Figure 4.4a) Total time immobile did not differ across days (F(1,41)=0.871, p=0.356) or across
genotypes (F(3,41)=2.272, p=0.095). (Figure 4.4b)
To evaluate anxiety-like behavior and follow up on the marked thigmotaxis in the OF
test, we used thigmotaxis in the elevated plus maze (EPM). (Figure 4.4c) Using one-way
ANOVAs, we found no significant differences in the time spent in the center (F(3,
21.335)=2.182, p=0.120), closed arms (F(3,21.022)=0.221, p=0.88), or open arms
(F(3,21.785)=1.656, p=0.206) of the maze.
As deficits in normal social behavior have been identified in studies of individual HRM
and DISC1 mutant mouse models, we used two types of social interaction tests to evaluate social
behaviors. In the dyadic test, mice paired randomly between the groups were allowed to explore
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Figure 4.4. HRM/DISC1 mice display normal affective behaviors but reduced preference for
social novelty (a)Porsolt forced swim test was used to evaluate depression-like behavior. Latency
to the first instance of immobility <2s, after the first 30s in the chamber. (b) Total time (s)
immobile during the last 2 minutes of the FST. (n=12-15) (c) Elevated plus maze was used to
evaluate anxiety-related behavior. Time spent in each area of the EPM, expressed as percent of
the total testing time. (n=8-17) (d) Social interaction in the dyadic test. Types of interactions
were manually scored by a blinded researcher. Interaction types stacked to visualize total social
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behaviors. (n=7-9) (e) Baseline social interaction in the 3-chamber social novelty test. Total time
spent interacting (facing, sniffing) with the novel juvenile, male mouse in chamber 1, compared
to time spent interacting with the empty chamber. Interaction was scored by hand for a tenminute period, following a 5-minute acclimation period during which no stranger mouse was
present. (n=7) (f) Preference for a novel stranger mouse in the 3-chamber social novelty test.
Interaction was scored by hand for a ten-minute period. (n=7) Outliers removed by individual
data points falling greater than 2 standard deviations from the mean. Two mice with outliers in
multiple measures were wholly removed from FST data. Data represented as mean ± SEM.

the open field together, and social behaviors were monitored and recorded. HRM/DISC1 mice
appear to spend less time engaging in social behaviors. While there were no significant
differences in one-way ANOVA results between in anogenital interaction (F(3,25)=1.299,
p=0.297), following (F(3,25)=0.732, p=0.543), sniffing (F3,25)=1.332, p=0.286), or total social
time (F3,25)=1.367, p=0.276), there was a large overall effect size for total social interaction
(Cohen’s f=0.4116). (Figure 4.4d)
A 3-chamber social novelty test was used to evaluate social interest in a juvenile male
mouse, as well as preference for novel versus familiar mouse. Baseline sociability with a
juvenile male (Stranger 1) was first established. A repeated measures ANOVA showed a
significant preference for Stranger 1 over the empty chamber in the opposite end of the apparatus

(F(1,23)=4.614, p=0.042), but no interaction with genotype (F(3,23)=0.335, p=0.877). (Figure
4.4e) During the second portion of the test, a second, novel stranger was introduced. A repeated
measures ANOVA showed a significant preference for the novel mouse (F(1,22)=5.231,
p=0.032), but no interaction with genotype (F(3,22)=0.335, p=0.800). (Figure 4.4f) However,
observing the behavior of each group independently, only WT mice showed a statistically
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significant preference for the novel mouse (t(11)=-4.298, p=0.001, Independent samples T-test).
HRM (t(11)=-0.560, p=0.586), DISC1 (t(12)=-1.532, p=0.152), and HRM/DISC1(t(12)=-0.611,
p=0.553) groups spend roughly the same amount of time interacting with the familiar and novel
mouse.
Cognitive behavioral assessment of HRM/DISC1 mice
The cognitive symptoms of SCZ are highly indicative of patient outcome, and
determining what level of cognitive impairment, if any, is present in our model is essential for
determining validity. To this end, we used several measures to detect differences in learning and
memory in WT, HRM, DISC1, and HRM/DISC1 mice.
In the radial arm water maze (RAWM), we examined the number of errors made during
the last trial on the last day of testing. During this trial, only one of 3 possible escape platforms
remains, the previous two platforms having been removed upon successful navigation of the test
mouse to the correct arm. While a clear trend in performance emerged, the performance of
DISC1 and HRM/DISC1 mice was variable compared to WT and HRM groups, which
comparatively made few errors. We counted the number of entries into arms that never contained
a platform as spatial memory errors, and while there were significant group differences
(F(3,10.531)=4.320, p=0.032, Welch’s ANOVA), Games-Howell post hoc tests were not
significant for individual differences between genotypes. (Figure 4.5a) Similarly, we found
significant group differences in working memory errors (defined as repeated entries in the same
arm of the maze) (F(3,11.546)=4.320, p=0.037, Welch’s ANOVA), but this was not driven by
significant differences between individual genotype groups. (Figure 4.5b)
While the RAWM results suggest a potential working memory deficit, in the Y-maze we
found no alteration in spontaneous alternation between HRM/DISC1 and any other group. We

84

Figure 4.5: Cognitive behavioral assessment of HRM/DISC1 mice. Radial arm water maze:
quantification of (a) spatial memory errors, classified as any entry into an arm of the maze that
never contained an escape platform. (b) working memory errors, classified as repeated entry into
any arm, and (c) escape latency. Visualization (d) of the nature of repeated arm entries, as a sum
of all errors made by each group, showing the proportion of re-entry into the most recent escape
arm. Ymaze: Quantification of (e) spontaneous alternation, calculated by (alternating triads/total
possible triads)*100, (f) freezing bouts of at least 2s in the center area of the maze, (g) time (s)
freezing in the arms of the maze (h) duration (s) of visits to the center of the maze. Fear
conditioning: percent time freezing during training during (i) training (j) in a familiar context (h)
before and after presentation of the conditioned stimulus in a novel context. Data represented as
mean ± SEM, except (d), which is represented as a sum for visualization only.
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detected a significant group difference (F(3,29)=3.113, p=0.043) driven by a reduction in
spontaneous alternation in the HRM group compared to WT (p=0.014) and DISC1 (p=0.018).
(Figure 4.5e)
To address the incongruity between our working memory results, we also asked if the
errors we classified as working memory errors in the RAWM might not indicate a working
memory deficit, but instead be evidence of perseveration or executive dysfunction. To begin to
address this question, we revisited our RAWM results and calculated an estimated time spent per
arm entry, finding significant group differences in entry duration (F(3,22)=3.053), p=0.050),
reflecting a lower entry duration in the HRM group compared to DISC1 (p=0.015) and
HRM/DISC1 (p=0.028). (Figure 4.5c) We also investigated the nature of the repeated arm
entries, and found that of the 33 total repeated arm entries made by HRM/DISC1 mice during the
last trial, 18 (54.55%) were repeated entries into the arm they most recently used to escape.
(Figure 4.5d) Statistical comparison of this measure to WT is not especially valuable, as most
WT mice made zero repeat arm entry errors, and only 5 in total, but reinforces the idea that
further investigation of perseveration or executive dysfunction is merited.
To further address the ambiguity in behavioral results, we investigated decision-making
behavior in the Y-maze by counting the number of freezing bouts in the center of the maze, as
well as the average duration of visits to the center. As WT mice had zero freezing bouts in the
center, we used an independent-samples Kruskal-Wallis test to determine differences, finding a
significant difference in distribution (χ2(3) = 10.640, p = 0.014). Post-hoc testing with the DunnBonferroni correction showed that this difference is driven by the increase in bouts between WT
and DISC1 groups (z= -12.571, p=0.021), and a trend in increase between the WT and
HRM/DISC1 groups (z= -10.786, p=0.074). (Figure 4.5f) As expected, this increase in freezing
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bouts was reflected in an increased length of time per visit to the center zone (F(3,29)=3.152),
p=0.042, one-way ANOVA) driven by differences between WT and DISC1 (p=0.013) and WT
and HRM/DISC1 groups (p=0.023). (Figure 4.5g)
We also followed up on the increased immobility behavior that a subset of HRM/DISC1
mice appeared to exhibit in the open field by calculating the time spent freezing in the arms of
the Y-maze, finding significant group differences (F(3,29)=3.762), p=0.023, one-way ANOVA)
driven by the increase in freezing in the HRM/DISC1 group compared to all other groups
HRM/DISC1 vs. WT (p=0.003) HRM/DISC1 vs. HRM (p=0.033), HRM/DISC1 vs DISC1
(p=0.049). (Figure 4.5h)
We also performed classical fear conditioning; however, interpretation of these results is
limited by the increased freezing in the HRM/DISC1 group seen in other tests. Indeed, we found
increased freezing in the HRM/DISC1 group compared to WT in the context test, confirmed by a
significant Welch’s ANOVA (F(3, 26.363)=5.440, p=0.005) with the Games-Howell post-hoc
test (p=0.004). (Figure 4.5i) In the cued test, there is a non-significant trend toward increased
freezing in HRM/DISC1 mice that fails to reach significance for the pre-conditioned stimulus
(F(3,49)=2.126, p=0.109) or post-conditioned stimulus (F(3,51)=2.323), p=0.086) time periods.
(Figure 4.5j) While a repeated measures ANOVA with the Greenhouse-Geisser correction was
significant by minute of the test for freezing during the training phase of testing
(F(3.756)=82.915, p<0.000) reflecting the increase in freezing following presentation of the
tone-shock pairing, there was no significant interaction between time and the genotype groups
(F(11.267)=1.543, p=0.117). (Figure 4.5k)
Results that depend on freezing or mobility measurements are difficult to interpret in
light of alterations in mobility displayed in the OF and Ymaze, which is an essential
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consideration for fear conditioning, and may at least partially account for the our inability to
detect an obvious affective deficit in HRM/DISC1 mice with the measures we used.
HRM/DISC1 mice display altered GABAA receptor expression and a paradoxical
reaction to diazepam
To determine whether the freezing behavior displayed across multiple behavioral tests
could be attributed to anxiety, we treated separate cohorts of WT and HRM/DISC1 mice with the
classic anxiolytic diazepam. We administered a single 1.5mg/kg dose via subcutaneous injection
and allowed them to explore the open field. We recorded behavior for 45 minutes to ensure we
were collecting accurate behavioral data, accounting for difference in subcutaneous absorbance
of the diazepam. Surprisingly, we found that the diazepam treatment exerted opposing effects on
WT and HRM/DISC1 mice. A two-way ANOVA showed a significant interaction between
diazepam treatment and genotype during the first 15 minutes of testing (F(1, 20)=9.156),
p=0.007), as treatment caused an increase in immobility for WT mice and decrease for the
HRM/DISC1 group, compared to vehicle-only treatment. (Figure 4.6a) Treatment also had
opposing effects on the time spent hiding in the corners of the maze from 15-30 minutes into
testing (F(1, 20)=8.160), p=0.010), and we observed a trend in this behavior during the first 15
minutes of testing (F(1,20)=3.986, p=0.06). (Figure 4.6b) As expected, WT mice spent less time
in the corners during the first 30 minutes of the test with diazepam treatment, while HRM/DISC1
mice spent more time in the corners.
As diazepam acts directly on GABAA receptors[40], we followed up on this finding by
investigating the level of GABAA receptor subtype expression in the hippocampus and

88

Figure 4.6: HRM/DISC1 have a paradoxical reaction to diazepam treatment and reduced
expression of subunit A1 containing GABA receptors. (a) Following subcutaneous diazepam
injection, immobility and (b) time (s) spent in the corners in the open field over 45 minutes, split
into 15-minute bins. (WT groups n=6, HRM/DISC1 groups n=7) (c) Western blots for GABA
receptor subtypes A1 and A5 in the prefrontal cortex (PFC) and the dorsal hippocampus (dHipp)
of WT, WT/tTa+, and HRM/DISC1 mice. (d) Quantification of GABA receptor subtypes A1 and
A5 in the prefrontal cortex and (e) hippocampus. Bands were normalized to actin and are
expressed as fold change from control. The WT control group includes WT and WT/tTa mice. (f)
Quantification of GABA receptor subtypes A1 and A5 in the prefrontal cortex and (g)
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hippocampus, with WT and WT/tTa mice treated as separate groups. Outliers removed by
individual data points falling greater than 2 standard deviations from the mean. Data represented
as mean ± SEM. #p<0.10, *p<0.05, **p<0.01

prefrontal cortex of WT and HRM/DISC1 mice using western blotting. (Figure 4.6c) We focused
on GABA receptor A1 (GABARA1) and A5 (GABARA5), as Guidotti’s group demonstrated a
paradoxical increase in locomotion with diazepam treatment in socially isolated mice, and found
associated changes in the expression of these receptors[41]. In the prefrontal cortex, we found
increased expression of GABARA1 (t(9)=-6.133, p<0.001), but not GABARA5 (t(5.310)=2.284,
p=0.068). (Figure 4.6d) We found no changes in the hippocampus in GABARA1 (t(10)=0.775,
p=0.217) or GABARA5 (t(10)=-0.118, p=0.909). (Figure 4.6e)
We also reanalyzed out western blot results to determine whether the expression of tTa
had any effects on GABA receptor subtype expression.(Figure 4.6f-g) While there was no
difference in GABARA1 between WT and WT/tTa groups in either brain area, we found that in
the PFC, GABARA5 expression in the WT group was distinct from the WT/tTa and
HRM/DISC1 groups (F(2,11)=8.355, p=0.009), representing a potential confounding effect of
tTa expression. Compared to WT, GABARA5 expression was reduced in the WT/tTa (p=0.02)
and HRM/DISC1 (p=0.004) groups, with WT/tTa and HRM/DISC1 groups had similar
expression levels (p=0.0.953).
Decreased density of parvalbumin positive cells, and increased number of
GAD67+/PV- cells in the medial prefrontal cortex of HRM/DISC1 mice
There is extensive evidence for alterations in inhibitory signaling in the prefrontal cortex
in SCZ[4, 42]. We investigated the effects of the combined genetic disruption on inhibitory cells
in the medial prefrontal cortex by determining the density of parvalbumin (PV) positive cells,
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and the occurrence of GAD67+/PV- cells. (Figure 4.7a) We found a decrease in the PV+ cell
density (t(24)=2.549, p=0.018) (Figure 4.7b) and an increase in the percentage of GAD67+ cells
that did not express PV (t(21)=-3.027, p=0.006). (Figure 4.7c)

Figure 4.7: Decreased density of parvalbumin positive (PV+) cells, and increased number of
GAD67+/PV- cells in the medial prefrontal cortex of HRM/DISC1 mice. (a) Quantification of the
total number of PV+ cells, presented as cells/mm3 (b) Percent GAD67+/PV- cells, calculated as
number of GAD67+/PV- cells/Total number of PV+ and GAD67+ cells (c) Representative 20x
micrographs. Arrows indicated GAD67+/PV- cells. Cells were counted exhaustively in six 40um
slices from 3 (WT) and 2 (HRM/DISC1) mice, using tiled, merged z-stacks of 6 confocal planes
taken at a 2µm interval. Data represented as mean ± SEM
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Impaired maturation of adult-born neurons in the dentate gyrus of HRM/DISC1
mice
Both reelin[43, 44] and DISC1[45] are involved in neuronal migration and maturation, so
we next examined adult neurogenesis, neuronal survival, and neuronal maturation in the dentate
gyrus (DG) of the hippocampus. We first used the synthetic thymidine analog 5-bromo-2'deoxyuridine (BrdU) to label dividing cells and identify changes in neurogenesis in the adult
DG. We injected BrdU for 3 consecutive days and collected tissue 3 days after the last injection,
then performed immunofluorescent staining to visualize newborn cells with incorporated BrdU.
We found group differences in the linear density of BrdU cells (F(3,68)=4.068, p=0.010, oneway ANOVA). DISC1 mice had significantly more BrdU+ cells compared to WT (p=0.017) and
HRM (p=0.001), while differences between HRM/DISC1 mice and both HRM (p=0.097) and
DISC1(p=0.090) were not significant. (Figure 4.8a)
To evaluate survival and differentiation of adult-born cells in the DG, we performed a
new set of BrdU injections, waiting 21 days to allow cells to differentiate and mature before
taking tissue. We performed immunofluorescent staining for BrdU and the neuronal marker
NeuN to identify mature, adult-born neurons. (Figure 4.8b-c) We counted the total number of
BrdU+ cells in the DG of the dorsal hippocampus, and the number of BrdU+ cells that did not
express NeuN, indicating differentiation into non-neuronal cell types. Compared to WT, we
found a large increase in the number of BrdU+ cells in HRM/DISC1 mice (t(40)=4.2425,
p=0.0001), and a smaller proportion of BrdU+/NeuN- cells (t(41)=31.742, p=0.039). (Figure
4.8d-e)
We used doublecortin (DCX) to identify immature neurons, and found no differences,
using unbiased stereological estimation to determine in the total number of DCX+ cells in the
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Figure 4.8: Characterization of adult neurogenesis and neuronal maturation in the HRM/DISC1
dentate gyrus. (a) Quantification of BrdU+ cells, counted in the whole hippocampus, 3 days after
injection. Cells were counted exhaustively from both hemispheres in four serial sections of 3
WT, 2 HRM, 2 DISC1, and 2 HRM/DISC1 brains. (b) Representative merged 40x z-stack
confocal micrographs, showing NeuN (red) and BrdU (green) positive cells in the adult dentate
gyrus of WT and HRM/DISC1 mice, 21 days after injection. (c) Representative 63x confocal
micrograph showing a BrdU+/NeuN+ cell in an HRM/DISC1 brain. (d) Quantification of BrdU+
cells in the medial dentate gyrus of the dorsal hippocampus, 21 days after injection. Cells were
counted from in the granular cell layer and hilus along an approximately 1mm length of
subgranular zone in both hemispheres of four serial sections from 3 WT and 3 HRM/DISC1
brains, from 6 tiled 400x confocal z-stacks with 7 planes at a 2µm interval. Linear density was
calculated by dividing the number of BrdU+ cells by the measured length of the subgranular
zone in each section and expressed as fold change from control. (e) Quantification of
BrdU+/NeuN- cells, indicating adult-born cells that differentiated into non-neuronal cell types.
All BrdU+ cells were assessed, and cellular colocalization was confirmed using orthographic
views, as necessary. (f) Stereological estimation of the total number of DCX+ cells in the dentate
gyrus. (g) Representative 40x magnification micrograph of DCX+ cells in an HRM/DISC1 brain.
Arrowheads indicated proliferative, category 1 cells. (h) Representative 10x magnification
micrographs of DCX staining in the dentate gyrus, demonstrating a lack of dendritic outgrowth
into the granule cell layer. (i) Quantification of DCX+ cell categorization. (j) Representative
images of cells which were categorized as: 1 - Proliferative, no dendritic processes; 2 Proliferative, 1 short process; 3 - Intermediate, medium process; 4 - Intermediate, medium
process that extends to the molecular layer; 5 - Mature, one dendrite branching in to the
molecular layer; 6 - Mature, delicate dendritic tree in granule cell layer. Outliers falling more
than 2 standard deviations from the mean removed. Data represented as mean ± SEM. # p<0.10

DG (F(3,19)=0.871, p=0.476, one-way ANOVA). (Figure 4.8f) To investigate maturation and
dendritic outgrowth in these cells, we used the schema developed by Plümpe et al. [46] to
categorize each DCX+ cell that was counted based on dendritic outgrowth.
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We found group differences in the number of immature, proliferative DCX+ cells.
(Figure 4.8g-h) A repeated measures ANOVA with the Greenhouse-Geisser correction showed a
significant effect interaction between category and genotype (F(8.798, 43.992)=2.416, p=0.026).
Individual ANOVAs for the different categories revealed differences in the number of cells in
categories 1 (F(3,18)=3.812, p=0.033) and 4 (F(3,18)=3.831, p=0.032), due to a large increase in
the number of immature cells in the HRM/DISC1 group (p=0.012 vs WT, p=0.014 vs HRM,
p=0.024 vs DISC1). This was balanced by a reduction in the number of cells in the intermediate
category 4 compared to WT (p=0.005) and DISC1 (p=0.029), but not HRM (p=0.152). (Figure
4.8i) There was also a trend toward differences in category 3 cells, and while it failed to reach
significance (F(3,18)=3.141, p=0.057), the group effect size (f=0.7262, Cohen’s f) suggests that
the lower number of category 3 cells in HRM/DISC1 hippocampi may be of interest.
Reduced dendritic spine density in HRM/DISC1 hippocampal dentate granule cells.
To further investigate the effects of reelin and DISC1 disruption on dendritic spines, we
used Golgi-cox staining to visualize a subset of neurons and counted dendritic spines in dentate
granule cells (DGC) and hippocampal pyramidal cells (HPC). (Figure 4.9a) We found no group
differences in linear spine density in secondary apical or primary basal dendrites of HPCs. While
we noted no group differences in a one-way ANOVA between all experimental groups, we noted
that an individual independent samples T-test reflects a reduction in DISC1 basal HPC linear
spine density compared to only to WT (t(39)=2.132, p=0.032). We found group differences in
spine density in dentate granule cells (F(3,57)=4.261, p=0.009), driven by a reduction in DISC1
(p=0.011) and HRM/DISC1 (p=0.007) brains compared to WT, and DISC1 (p=0.036) and
HRM/DISC1 (p=0.036) brains compared to HRM.
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Figure 4.9: Reduced dendritic spine density in HRM/DISC1 hippocampal dentate granule cells.
(a) Representative 100x micrographs, cropped from single planes of z-stack images of
hippocampal dentate granule cells (DGC) in WT and HRM/DISC1 brains, visualized using the
Golgi-cox impregnation and staining method. Yellow box denotes ~20µm long counting area.
Counts were normalized by the actual measured length of the segment counted to generate a
linear density of spines (spines/µm) (b) Quantification of linear spine density in DGC,
hippocampal pyramidal cell (HPC) apical dendrites, and HPC basal dendrites. 3-5 brains per
group were stained and imaged. Number of dendrite segments counted: DGC: WT=27;
HRM=11; DISC1=8; HRM/DISC1=16. HPC apical: WT=18; HRM=11; DISC1=14;
HRM/DISC1=20. HPC basal: WT=18; HRM=11; DISC1=18; HRM/DISC1=23. Outliers falling
more than 2 standard deviations from the mean removed. Data represented as mean ± SEM.

Discussion
Current studies on the etiology of SCZ often incorporate gene-environment interaction
models, usually combining an external environmental factor with a disrupted gene of interest. In
this model study we consider the genetic environment of SCZ, a complex and polygenic disease.
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We increase the genetic load of putative SCZ vulnerability genes, combining expression of
dominant-negative C-terminal truncated human DISC1 with reelin haploinsufficiency.
We established that adult male HRM/DISC1 mice are of normal weight and experience
typical nociception. We found no alterations in affect in our assays, and only subtle changes in
sociability. While this is contrary to results of altered social behavior in the dyadic test reported
for the individual DISC1 mouse[13], this can potentially be attributed to differences in
methodology. Our dyadic social interaction tests paired non-littermate mice randomly from all
groups, and while we measured social behaviors initiated by each mouse, these behaviors were
likely limited by variations in social reciprocation and the mobility of mice. Our 3-chamber
sociability test eliminated some of these issues but measures only male to juvenile male
sociability. We found no difference in baseline social interaction in this test but found a reduced
preference for social novelty. Only the WT group preferred the novel mouse, while HRM,
DISC1, and HRM/DISC1 mice spend roughly the same amount of time with the familiar and
novel mice.
Sleep disturbances are common in neuropsychiatric disorders, and may have a genetic
basis in SCZ[47]. We found subtle alterations in circadian rhythms in HRM/DISC1 mice.
Equivalent RA, IV, and IS suggest no severe circadian deficit, with relatively strong, stable
circadian rhythms with little fragmentation. However, while all groups successfully entrained to
12:12 LD, and had normal free-running period in DD, HRM, DISC1 and HRM/DISC1 mice had
longer periods during a phase shift. HRM/DISC1 mice also had fewer bouts of activity per day.
However, this data represents only voluntary wheel running. It is possible that sleep is still
fragmented, but not marked by bouts of activity, an idea supported by the overall reduced
number of bouts combined with increased immobility in other tests.
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Working memory deficits are common in patients with SCZ, and are associated with
dorsolateral prefrontal cortex dysfunction[48, 49]. While our molecular results suggest that
HRM/DISC1 may have some level of inhibitory imbalance in the PFC, we did not find a
convincing working memory deficit in our behavioral assay. HRM/DISC1 and DISC1 mice
made in increased number of repeat-entry type errors in the RAWM, but we were only able to
detect a reduction in spontaneous alternation in the HRM group in the Y-maze. While repeated
arm entries in the RAWM can be attributed to a working memory deficit, we observed that many
of these errors were repeated entries into the most recent escape arm. We believe that these
errors may be due to other, more subtle alterations in cognitive function that merit further
investigation.
Deficient inhibitory output in the PFC may impact working memory and other cognitive
functions in patients with SCZ. A reduction of the 67 kDa isoform of glutamic acid
decarboxylase (GAD67) in PV+ cells in the dorsolateral PFC is a consistent finding in patients
with SCZ. Human fMRI studies comparing prefrontal cortex activation during working memory
task performance between healthy controls and patients with SCZ have demonstrated prefrontal
cortex inefficiency - some SCZ patients perform similarly to controls but use greater prefrontal
cortex resources[50]. This finding is not limited to working memory, as neural inefficiency has
been reported in response to other tests of executive function including verbal fluency[51] and
logical reasoning[52] and may be dependent on the precise cognitive demands of individual
tasks[53, 54].
We found a reduction in the total number of PV+ cells in the medial PFC of HRM/DISC1
mice, and an increased proportion of GAD67+/PV- cells, suggesting that the alteration in cell
number may be specific to PV+ cells, rather than an overall decrease in GABAergic cells in the
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PFC. Our model expresses c-terminal truncated DISC1, the expression of which is limited in the
PFC to pyramidal cells[55, 56], whereas reelin, reduced by ~50% in the HRM, is expressed by
GABAergic interneurons. A potential mechanism for altered behavior in the HRM/DISC1 model
is reduced inhibitory output by PV+ GABAergic interneurons onto PFC pyramidal neurons. One
of the most consistent clinical finding in SCZ patients is abnormal gamma band oscillations[57].
Gamma oscillations (~25-100hz) are generated and synchronized through inhibitory feedback by
fast-spiking PV+ interneurons onto pyramidal neurons during a range of cognitive processes [5860], and are involved in sensorimotor integration[61].
PPI of the acoustic startle response is used as a translatable measure of sensorimotor
gating in both human and animal testing. We found a reduction in startle response in
HRM/DISC1 mice, as well as decreased prepulse inhibition in all groups at the 82db prepulse
level, and DISC1 and HRM/DISC1 groups at the 86dB prepulse level. Abnormal startle response
and PPI has been reported in the HRM[62], but has not been consistently reproduced, and is
sensitive to age and PPI modality[63]. While PPI deficits have been reported in several models
of DISC1 disruption, a reduction was only evident in the 74dB prepulse in studies on a
dominant-negative DISC1 model generated on a pure C57/Bl6 background[64], and not at all in
the mixed-background dominant-negative DISC1 mouse[13].
Given the role of reelin signaling in synaptic plasticity in the adult brain, we expected
some level of cognitive deficit to be reflected in this model, despite a lack of differences in
learning and memory reported in the C-terminal truncated DISC1 model. Our behavioral results
yielded only trends toward increased errors in the RAWM. The reduced exploratory behavior in
the OF, decreased mobility in other tests, and reduction in bouts of voluntary wheel-running
activity complicate interpretation of the behavioral phenotype. This is particularly relevant to
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classical fear-conditioning, as freezing behavior is used as a measure of fear to indicate memory
of the aversive stimuli. Any potential fear conditioning deficits could be masked by on overall
increase in freezing behavior. Investigation of some of the kinds of cognitive functions, like
verbal fluency and logical reasoning, is not easily achievable in rodent studies. However, future
work using this model should include an expanded range of cognitive tests that are sensitive to
perseveration, attention, cognitive flexibility, and decision-making using outcome measures that
do not rely on freezing.
We considered the possibility that the reduction in exploratory behavior and immobility
observed in HRM/DISC1 mice might be related to anxiety, despite normal EPM performance. In
general, none of the groups spent much time exploring the open arms of the EPM, potentially
due to the tests being conducted with overhead lighting rather than dim red light. A floor effect
could mask an anxious phenotype. Administration of an anxiolytic, diazepam, unexpectedly had
opposite effects on HRM/DISC1 mice compared to the WT, failing to rescue the deficit in
exploratory behavior in HRM/DISC1 mice: increasing time in the corners of the apparatus and
increasing mobility. While we attempted to administer a dose of diazepam that would have
anxiolytic but not sedative effects, it is possible that the increase in immobility in WT mice could
be attributed to some level of sedation. We would expect that the observed increase in the
expression of A1-containing GABA receptors in HRM/DISC1 mice might further increase this
effect, rather than the opposite effect we observed. While these results point to changes in
inhibitory signaling in HRM/DISC1 mice, it is limited to the expression of only A1 and A5
GABA receptor subtypes, and a complete picture of overall GABA receptor expression is
necessary to completely interpret these results. We also observed a trend toward a decrease in
A5-containing

GABA receptors in the PFC, but separately analyzing mice from the WT group
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that also expressed tTa suggests that the effect might be due to tTa expression. While this only
reflects data from a very small number of mice, it should be further investigated, especially
considering the prevalence of tTa in transgenic mouse models and some evidence for other offtarget effects[65, 66].
Defects in adult hippocampal neurogenesis have been reported in patients with SCZ and
in multiple animal models. While we found no overall decrease in the number of proliferating
cells in the adult hippocampus of HRM/DISC1 mice, we found that immature neurons have
reduced dendritic outgrowth during the DCX-expressing stage of maturation. We also found an
increased number of BrdU+ cells in the in the dentate gyrus of the dorsal hippocampus of the
HRM/DISC1 brain, a lower proportion of which were NeuN-, indicating differentiation into nonneuronal cell types. Taken together, these results indicate a similar rate of neurogenesis, but
suggest that the processes underlying the survival and maturation of adult-born neurons in the
hippocampus are altered in the HRM/DISC1 brain. Programmed cell death (PCD) is one of the
essential regulatory functions involved in adult neurogenesis, with the most extensive PCD
occurring during synaptogenesis in postmitotic neurons, resulting in a loss of 30-70% of
immature neurons[67, 68].
We found reduced DGC spine density in dentate granule cells of both DISC1 and
HRM/DISC1 mice, and no differences in spine density in basal or apical dendrites of HPCs.
Reduced basal HPC spine density has been reported in the HRM[69], and reduced spine density
has been consistently observed in many DISC1 mutant models[70]. Interestingly, Pletnikov’s
group reports an increase in spine density in DGCs in the c-terminal truncated DISC1 model[71],
and reduction in response to maternal immune activation in a separate study[72]. We performed
our Golgi-cox staining on brains from the cohort of mice used for our circadian experiments.
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Mice were returned to home cages and a typical 12:12 light-dark schedule one week before
brains were taken, and we compare only between mice with the same caging and enrichment.
However, the period of social isolation and the availability of enrichment in the form of the
activity wheel in the circadian cages may have had an effect on dendritic spine density. This
should be considered when comparing this data to dendritic spine density data collected by other
groups.
One possible reason for the incongruity between dendritic spine counts in the c-terminal
truncated DISC1 model is reactivity to an environmental factor such as stress or social isolation.
Additionally, physical exercise is well-known to increase dendritic spine density in the
hippocampus[73]. As HRM have been described as having a dampened responsiveness to
environmental challenges[74], one possible explanation for our results is that voluntary exercise
may have increased spine density in all groups, while DISC1 and HRM/DISC1 mice may be
more sensitive to social isolation or stress compared to HRM. These results encourage
exploration of dendritic spine density in gene-environment interactions with this model.
There are several important considerations for continued exploration of this gene-gene
interaction model. We established a behavioral profile for adult mice, with possible mechanisms
for some of the alterations. SCZ has a temporal profile of susceptibility, with behavioral changes
beginning in the pubertal period[75]. Determining which of these behavioral, cellular, and
molecular changes we show in HRM/DISC1 mice are present in juvenile mice will be useful for
determining how they contribute to susceptibility to the external environmental insults. This
study is also limited to male mice. Human SCZ is equally prevalent amongst men and women,
but has differences in symptomatic presentation, outcomes, and healthcare needs[76]. Sex
differences in HRM/DISC1 mice are likely present, and have been reported in both individual
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HRM and DISC1 models, including cognitive deficits[71] and depression[13] exclusive to
female DISC1 mutant mice. Finally, future work should include expression studies confirming
mRNA levels and localization of mutant DISC1 and reelin proteins in the HRM/DISC1 brain.
There is no established causal relationship between reduced reelin and SCZ, raising the
possibility that the reduction in expression is a symptom of the disease[77, 78]. The RELN
promotor is likely under epigenetic control[77, 78], and along with the GAD67 promotor, is
downregulated by methylating enzyme DNA methyltransferase 1 (Dnmt1)[79]. Altered DNA
methylation has been associated with the DISC1 translocation in humans[80], as well as various
environmental factors linked to SCZ etiology[81]. It is possible that epigenetic modulation could
lead to a further reduction of reelin expression in the HRM/DISC1 mouse, a factor that must be
considered in gene-environment studies using this model.
In summary, we identified alterations in neuronal maturation and dendritic outgrowth in
the hippocampus, alterations in GABAergic cells in the prefrontal cortex, and a complex
behavioral profile best described by intact affect, reduced voluntary mobility, a strong
sensorimotor gating deficit, and subtle changes in cognition. While we related our findings to
translatable measures in human SCZ patients, this study provides valuable insight into the
contributions of reelin and DISC1 to adult neurogenesis and behavior.
Methods
Animals
To generate a gene-gene interaction model of DISC1 and Reelin disruption, we bred
double transgenic mice with inducible mutant human DISC1 with heterozygous reeler mice
(HRM) to produce a triple transgenic mouse line.
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The inducible human DISC1 mouse was provided by M.V. Pletnikov’s group (Johns
Hopkins University School of Medicine, Baltimore, MD, USA). In brief, a Tet-off double
transgenic system was used, and founder mutant human DISC1 mice were bred with single
transgenic B6;CBA-Tg(Camk2a-tTA)1Mmay/j mice (The Jackson Laboratory, Bar Harbor, ME,
USA) expressing tetracycline-transactivator (tTa) driven by the calcium-calmodulin-dependent
kinase II-α (CAMKII) promoter. This results in constitutive expression of mutant human DISC1
primarily in excitatory forebrain neurons that may be turned off my administration of
doxycycline (DOX) in mouse chow. (See Pletnikov, et al. 2008 for detailed methods) [13, 82]
DOX was not administered for these experiments. Expression of mutant human DISC1 and tTa
were confirmed via polymerase chain reaction. “DISC1” refers to mutant human DISC1 and tTa
positive mice throughout the manuscript.
HRM (B6C3Fe a/a-Relnrl/+ strain) mice were originally obtained from The Jackson
Laboratory. DISC1 mice were crossed with HRM to obtain a double transgenic mouse line and
were back-crossed to C57Bl/6J wild type mice.
In order to minimize the number of mice necessary, we included mice expressing only
tTa and not DISC1, or only DISC1 and not tTa in out WT and HRM control groups. We could
detect no behavioral differences within these groups, however, we found potential differences
between WT and WT/tTa groups in our GABA receptor subtype assay. These results reflect only
2 tTa mice but will be an important consideration moving forward.
All animal testing procedures and care followed the NIH guidelines and were approved
by the University of South Florida’s Institutional Animal Care and Use Committee.
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Behavioral testing
All behavioral tests are performed on groups of male mice, 2-6 months of age. Except for
circadian assessment, all mice were group housed in standard LD, fed standard mouse chow ad
libitum, and all tests were performed during the animals’ light cycle. Mice were allowed 30-60
minutes to acclimate to behavioral testing areas before beginning tests. Each apparatus was
thoroughly cleaned with 70% ethanol between mice to minimize scent cues. White noise was
played in behavioral areas.
Exploratory behavior and mobility were tested in the open field (OF). Mice were placed
in the center of a (27 × 27 cm) box evenly lit from above and allowed to explore for 10 minutes.
Behavior was recorded and tracking was scored automatically by ANY-maze software (Version
6.06, Stoelting, Wood Dale, IL).
To assess locomotor circadian activity mice were moved to individual housing, equipped
with monitored running wheels, in sound attenuated and light-controlled chambers. (Lafayette
Instrument, Lafayette, IN) Activity was recorded using Scurry Activity Monitoring Software
(Lafayette Instrument, Lafayette, IN). Typical 12:12 light-dark (LD) activity was measured for
11 days before a 5-hour phase advance (Shift, lights on and lights off time moved 5 hours later in
the day). After one week, all lights were turned off to measure free-running activity in constant
darkness for two weeks. Mice were returned to standard LD conditions before use in molecular
experiments. Activity was analyzed using ClockLab Analysis software (ClockLab, Actimetrics,
Wilmette, IL), as previously described by our group[83]. Light and temperature in the chambers
were monitored using HOBO Pendant Temperature/Light 8 K Data Loggers (Onset Computer
Corporation, Bourne, MA).
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Nociception was evaluated using a hot plate test (Ugo Basile), to ensure that allodynia or
hyperalgesia effects would not impact fear conditioning results that were dependent on foot
shock. Plate temperature was fixed at 55°C. Mice were carefully monitored for hind-leg flick
response (or any other indicator of distress) and removed promptly.
Pre-pulse inhibition (PPI) testing was performed to assess sensory gating. Animals were
placed in a clear, cylindrical restrainer (Panlab, Barcelona, Spain) inside a sound-attenuation
chamber. Animals were acclimated for 5 minutes in the presence of 65dB white noise then were
presented with seven trial types in a pseudorandom order with an inter-trial interval of 10 to 20s:
a 40 ms, 120 dB sound burst (startle); 74, 78, 82, 86, and 90 dB acoustic pre-pulses preceding a
120dB sound burst by 100ms; and no stimulus. Startle responses were measured as force and
latency to response using an accelerometer located beneath the restraint platform. Percent PPI
was calculated using the formula: [100 − (response to pre-pulse + 120 dB) / (response for 120 dB
alone) × 100].
Forced swim test (FST) was used to measure depression-like behavior. A two-day testing
paradigm was used, in which animals learned on the first day that escape is not possible. Each
day, animals were placed in warm water in a 5L beaker (27±2°C, diameter: 20 cm, water depth:
12cm), and allowed to remain for 6 minutes. The beaker was placed within the open field
apparatus to prevent visualization of the researcher or other animals during testing. The test was
recorded by overhead digital camera, then immobility was scored by a researcher blinded to the
experimental conditions. Latency to immobility was quantified following a thirty second period
of acclimatization, and percent time spent immobile was quantified during the last 2 minutes of
the test.
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Elevated plus maze (EPM) was used to evaluate anxiety. The apparatus consisted of four
arms, elevated 40cm from the surface: two opposite open, well-lit arms (30 x 5 cm), and two
enclosed arms (30 x 5 x 15 cm), each attached to an open (4.5 cm square) center platform.
Animals were placed on the center platform and allowed to explore for 5 min. Activity was
monitored by an overhead digital camera, and the ANY-Maze animal activity system (Stoelting
Co.) was used to record and analyze mice behavior. Anxiety levels were assessed by ratio of time
spent in the open:closed arms.
Social behavior was assessed using a social interaction test (SI) in an open field
apparatus. Sex-matched non-cagemates were placed in a lit box (40 x 40 x 27 cm) for 10 min.
Activity was recorded using a digital camera, and the video evaluated by a researcher blinded to
the experimental conditions. For each animal, time spent sniffing, following, and engaging in
anogenital interaction was recorded, and a total social time calculated as the sum of these
activities. The animal being assessed was considered to be sniffing if its head was within 2
inches of the other animal, following if moving in the same direction from within 5 inches
behind for at least 2 seconds, and engaging in anogenital interaction if the sniffing behavior
occurred within 2 inches of the rear of the other animal. The number of seconds of each activity
were expressed as a percentage of total test time.
Social preference and social memory were assessed using a 3-chambered social novelty
box (60 × 24 cm total), with an empty central area separated on either side by Plexiglas from two
areas containing removable wire cups. For the first 5 minutes of the test, the mouse was placed in
the empty central area of the box with two removable plastic doors preventing movement into
the side chambers. After 5 minutes of acclimation, a juvenile, male, stranger mouse was placed
in one of the wire cups (alternating sides) and the doors were removed to allow the mouse to
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explore for 10 minutes. After ten minutes, a new stranger was placed in the other wire cup and
the mouse was allowed another 10 minutes to explore. Interactions were scored manually from
video recordings by a researcher blinded to the experimental groups.
Cued and contextual fear conditioning (FC) were used to evaluate fear-based learning and
memory. Animals were tested as previously described. (Weeber et al., 2002) Briefly, animals are
trained in the fear conditioning apparatus with two 30s acoustic conditioned stimuli (CS), each
paired with an unconditioned stimulus (US): a 0.5mA foot shock. To assess contextual fear
conditioning, mice were placed back into the same context for 3 minutes, 24 hours following the
CS-US pairings. To assess cued fear conditioning, mice were placed in a novel context, allowed
to acclimate for 3 minutes, then presented with the acoustic CS for 3 minutes. Tests were
recorded, and fear response was assessed as freezing. Tests were scored by a researcher blinded
to the experimental conditions, and the animal was considered to be freezing in the absence of
movement with the exception of respiration.
We used a 6-arm radial arm water maze (RAWM) test, using an apparatus with arms
measuring 20 x 35 cm in a circular pool, with a 40 cm diameter center area. Escape platforms
were removable clear Plexiglas, magnetically affixed to the end of each escape arm with ~1cm of
water over the surface. Water was made opaque with white, non-toxic paint. Mice were trained
in 3 trials per day for 4 days. For trial 1 the mouse was placed in the starting arm, which
remained consistent throughout all tests, and was allowed to explore for 2min or until it
“escaped” by finding one of three available escape platforms. After 30s to reference large,
brightly colored spatial cues placed around the pool, the mouse was removed, gently dried, and
placed in a warmed holding cage for 2 minutes. For trial 2, the process was repeated with the
escape platform used in trial 1 removed, and this process repeated for trial 3. Testing was timed
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and scored in real time by a researcher blinded to the experimental groups. Spatial memory
errors were considered entries into any arm that never contained a platform and working memory
errors were considered repeated entry into any arm. A recorded entry required all 4 paws inside
the arm of the maze. Testing continued until all groups reached the final platform with an
average of <20 seconds.
We measured spontaneous alternation task in the Y-maze apparatus, which consisted of
three arms (38 x 8 cm) connected at 120° angles from each other, evenly lit from above. Mice
were allowed to explore for 8 minutes, starting in one arm of the maze. Total entries, order of
entries, and freezing behavior was recorded.
Diazepam treatment
To determine whether anxiety-like behaviors could be rescued with anxiolytic treatment,
a separate cohort of mice that had not previously been exposed to the OF apparatus were
acclimated to handling for 3 days prior to treatment. Mice were treated with 1.5mg/kg diazepam
(7-Chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one) (Sigma), diluted in sesame oil
(Sigma) via subcutaneous injection, or sesame oil only. Mice were placed into an individual
standard cage and transported to the behavioral room containing the open field. Mice were
placed in the open field and allowed to explore for 45 minutes, and analysis was split into 15minute bins.
Western blotting
Mice were briefly anesthetized using isoflurane and sacrificed by rapid decapitation.
Brains were dissected immediately to collect hippocampus, cortex, and prefrontal cortex, and
snap frozen on dry ice.
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Western blotting was performed as previously described[83]. Tissue lysis was achieved
by sonication in Mammalian Protein Extraction Reagent (M-PER) with phosphatase and protease
inhibitors (10 µl/ml, Halt™ Protease and Phosphatase Inhibitor Cocktail, Thermo Scientific Inc,
Rockford, IL, USA) clarified by centrifugation at 20,000 g at 4 °C for 20 min after a 15 minute
incubation. Total protein concentrations were determined by BCA assay (Thermo Scientific),
and equal amounts of protein were resolved on 9% tris-glycine acrylamide gels. Proteins were
transferred for 1 hour on ice, and nitrocellulose membranes were blocked in 5% milk in tris
buffered saline with 0.1% tween-20 (TBS-T) before primary antibody incubation. When blots
were probed for multiple proteins of different sizes, membranes were stained with Ponceau stain
before blocking and cut. Membranes were incubated in 2% milk in TBS-T with primary antibody
overnight, then rinsed in TBS-T and incubated in 2% milk in TBS-T with 1:7500 HRPconjugated secondary antibody for 2 hours at room temperature. Rinsed blots were imaged with
an image analyzer (Amersham Imager 6000), visualizing bands using enhanced
chemiluminescence (ECL, Thermo scientific). Densitometry was performed with Image Lab
(Bio-Rad Laboratories, Hercules, CA), and bands of proteins of interest were normalized to betaactin.
Immunohistochemistry and analyses
A subset of mice from each group was deeply anesthetized with sodium pentobarbital or
isoflurane and transcardially perfused with saline, followed by 4% paraformaldehyde. Brains
were post-fixed in 4% formaldehyde for 48 h at 4 °C, cryoprotected in 30% sucrose in
phosphate-buffered saline, and then sectioned coronally on a vibratome or sliding microtome at a
thickness of 40μm.
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We visualized fast-spiking interneurons in the prefrontal cortex using immunofluorescent
staining for parvalbumin (PV), and inhibitory cells using GAD67 as a marker. Three to four
sections containing prefrontal cortex were selected and rinsed in phosphate-buffered saline
(PBS). Antigen retrieval was performed in 2N HCL for 1 hour at RT, followed by tissue
permeabilization in 0.1% triton-x in PBS. Tissue was blocked for 1 hour at RT in 5% normal
goat serum with 0.1% bovine serum albumin and 0.3% triton-x in PBS. This solution was used
as the antibody dilution solution (ADS). Sections were incubated overnight at 4C in primary
antibodies against PV (1:1000, mouse, Sigma Aldrich) and GAD67 (1:500, mouse, Sigma
Aldrich) in ADS. Sections were protected against light from this point forward. After thorough
rinsing in PBS, sections were incubated in goat anti-mouse iGg1 Alexa fluor 488 and goat antimouse iGg2a Alexa fluor 594 (1:500, Life Technologies) for 2 hours at RT in ADS.
We visualized adult-born cells and mature neurons in the hippocampus using
immunofluorescent staining for BrdU and NeuN. We selected 6 sections containing
hippocampus at a 480µm interval, beginning with the most rostral hippocampal section. We used
the same immunofluorescence procedure outlined above, using primary antibodies raised against
Brdu (1:250, mouse, Cell Signaling Technology) and NeuN (1:250, rabbit, Cell Signaling
Technology), and goat anti-mouse Alexa fluor 488 and goat anti-rabbit Alexa fluor 594 (1:500,
Life Technologies) secondary antibodies.
Sections were rinsed in PBS, mounted on charged slides, and allowed to dry for 30
minutes. When dry, sections were rinsed with MilliQ water, allowed to dry, and coverslipped
with Prolong gold antifade reagent with DAPI.
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Imaging for the 3-day post-injection BrdU study was done using a Zeiss AxioScan.Z1
slide scanner to capture stitched digital images of whole sections. BrdU+ cells were identified by
hand by position and morphology and counted exhaustively in the entire dentate gyrus.
PV/GAD67 and BrdU/NeuN images were acquired using a Zeiss LSM 880 confocal laser
scanning microscope using equal laser intensity and exposure between compared images. Cells
were counted in ImageJ by creating merged, maximum intensity z-stack projections.
Colocalization was confirmed in Zen Blue 3.2 by using orthographic z-stack views.
We visualized immature neurons using doublecortin (DCX). DCX
immunohistochemistry was performed as previously described (Lussier et al., 2013). Briefly,
antigen retrieval was performed on free-floating tissue sections by incubation in sodium citrate
(6.0 pH, 95°C, 30min). Sections were then incubated with rabbit anti-DCX monoclonal antibody
(1:1000; diluted in 5% NGS, 1% BSA, 0.5% Triton-x 100 in PBS, 24h). Day 2, sections were
incubated in H2O2 (5%, 30min), followed by biotinylated secondary antibody (goat anti-rabbit,
Southern Biotech, 1:500, diluted as above, 1h), and an avidin-biotin peroxidase complex (1:500,
Vector Labs, 1h). Immunolabelling was visualized with 0.025% diaminobenzidine, 4.167%
nickel ammonium sulfate, and 0.002% H2O2 diluted in 0.175 M sodium acetate. The reaction
was stopped using 0.175 M sodium acetate as a rinse. The sections were rinsed in PBS, mounted,
and cover slipped using DPX mountant.
DCX+ cell number was quantified using unbiased stereology in Stereo Investigator 11.03
(MBF Bioscience, Williston, VT USA), at 400x on a (microscope info) brightfield microscope
equipped with a motorized stage (company info). DCX+ cells were counted using the optical
fractionator method.(West et al., 1991) The subgranular zone and granule cell layer in both
hemispheres were selected as the region of interest and traced at 100x closely following cell
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bodies in 5 sections per subject, at an evaluation interval of 12. A mounted thickness of 20 µm
was used, with 2µm guard zones at the top and bottom of each section. A sampling grid size of
150 µm × 150 µm was placed randomly over the ROI to position the 50 µm × 50 µm counting
frame in xy-axis. Approximately 200-300 cells were counted per subject, and the total number of
cells calculated using the following formula Ntotal: ΣQ− × t/h × 1/asf × 1/ssf, where Q- is the
number of DCX+ cells counted, t is the mounted thickness of the sections, h is the counting
frame height, asf is the area sampling fraction, and ssf is the section sampling fraction[84, 85].
Characterization of immature neurons in the dentate gyrus was performed to produce a
semiquantitative description of DCX+ cell development. The dendritic branching of all cells
within the stereological counting frame were categorized as previously described[26, 46]. Each
cell was categorized as 1-6 based on the extent of its dendritic processes. Categories 1 and 2
defined cells in the proliferative stage with no processes, or one short process. Categories 3 and 4
defined intermediate cells with one medium process or one process reaching into the molecular
layer. Categories 5-6 defined cells in the postmitotic stage with one secondary dendritic branch
in the molecular layer, or a delicate, well-defined dendritic tree.
Golgi impregnation, dendritic spine counting, and characterization
We used Golgi-Cox impregnation to visualize dendritic spines in a subset of neurons,
allowing us to count and characterize spines in the hippocampus. We deeply anesthetized 4 mice
per group with isoflurane and performed rapid decapitations. Brains were cut along the midline,
and both hemispheres were rinsed in Milli-Q water and placed immediately in impregnation
solutions. Golgi-cox impregnation was performed according to protocol using the FD Rapid
GolgiStain Kit (FD Neurotechnologies). Briefly, tissue was stored in the dark in impregnation
solution for 3 weeks and gently agitated daily, then moved to Solution C. Tissue was rapidly
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frozen in dry-ice cooled isopentane and stored at -80C until sectioned at 100µm using a cryostat
and mounted on gelatin-coated slides. Mounted tissue was stained using freshly mixed Solution
D/E, dehydrated in an ethanol series, and cover slipped using Permount mounting medium.
Slides were imaged using a 60X UPlan FL N 1.25 NA Oil Iris objective on an Olympus
BX53 digital microscope. Primary basal dendrites and secondary apical dendrites were imaged
from hippocampal pyramidal cells. Secondary dendrites were imaged from dentate granule cells.
Dendritic spines were counted manually from z-stack images of various depth, along an
approximately 20µm length of the dendrite of interest, starting at least 5µm from any branch
point. The actual length of the counted segment was measured and used to generate the linear
density.
Statistical analysis
One-way ANOVA was used to determine group differences unless otherwise indicated in
the text. Significant main effects of genotype were further assessed using LSD post-hoc tests.
Levene’s test of homogeneity of variances was used, and if significant, Welch’s test of equality
of means was used in place of ANOVA to determine group differences, followed by post-hoc
testing using the Games-Howell correction. Repeated measures ANOVA was used to evaluate
group differences in Rotarod, RAWM, FC, FST, and DCX+ cell categorization. Independent
samples 2-tailed t-tests were used to analyze GABA receptor, PV/GAD67, BrdU, and NeuN
expression results. Outliers were excluded by data point if values were outside 2 standard
deviations from the group mean unless otherwise indicated. The criterion for statistical
significance was set at p<0.05. Statistics were performed using IBM SPSS Statistics 22 (SPSS,
Inc., Chicago, IL, USA). Data are presented as mean ± SEM, unless otherwise indicated in the
text.
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Chapter 5: Closing remarks and future directions

The cognitive testing requirements between the two studies presented here differ in two
dimensions – both the direction of hypothesized change and the complexity of the question. By
administering the CK1 inhibitor PF670462 to otherwise healthy mice, we asked whether we
could increase general cognitive performance, and demonstrated a modest effect across several
tests. The results of the CK1 inhibition study are an intriguing step into the potential of circadian
rhythms as a target for cognitive enhancement. The next step is to bring these studies together
and determine the ability for CK1 inhibition with PF670462 to rescue the circadian and cognitive
defects in the HRM/DISC1 mouse.
The circadian phenotype of HRM/DISC1 mice requires more careful attention. There was
a large effect of genotype on the length of the free-running period, but this effect was not
statistically significant. The results were highly variable, and it appears possible that a subset of
HRM/DISC1 mice might have more severe circadian alterations. This is evident when we
compare the activity patterns between a typical WT mouse, and three different HRM/DISC1
mice over several days of constant darkness, (Figure 5.1) and demonstrates the need for a more
thorough investigation into the circadian phenotype of HRM/DISC1 mice. One possible
explanation for this is an exaggerated reaction to the social isolation necessary to measure
activity rhythms. Sleep studies on patients with SCZ have also demonstrated marked phenotypic
variability ranging from typical circadian entrainment to highly disrupted and irregular sleep
cycles[1].
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Figure 5.1: Variability in the circadian rhythms between individual HRM/DISC1 mice.
Representative actograms, demonstrating marked differences in free running in constant
darkness between individual HRM/DISC1 mice, compared to WT (top). Actograms are double
plotted, showing 48 hours of recording across the x-axis. Black bar denotes lights off, black ticks
denote activity, rows represent days of activity recordings.

In our characterization of the HRM/DISC1 mouse model, we expected a reduction in
cognitive performance that would be translatable to SCZ. The profile of cognitive alterations in
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SCZ is as complex as the disease itself and investigating it in a mouse model presents a unique
set of problems.
While this initial characterization of HRM/DISC1 mice has yielded useful data, it has
also produced as many questions as it has answered. Diazepam treatment directed our
investigation toward α-subunit containing GABA receptors but failed to actually answer the
question of whether HRM/DISC1 mice have an anxious phenotype.
The cognitive profile of HRM/DISC1 mice is intriguing, but incomplete. We initially
attempted latent inhibition but abandoned testing with the discovery of increased freezing across
other tests, as any deficit would likely be masked in the same way they might be in the fear
conditioning results we reported. Thorough characterization of cognitive function in the
HRM/DISC1 mouse as a model for SCZ or other neuropsychiatric diseases will require an
expanded behavioral testing paradigm. One option may be the five-choice serial reaction time
task (5-CSRTT)[2, 3], a reward-based operant conditioning task that does not rely on freezing
measures. Variations on the 5-CSRTT can examine sustained attention, impulsivity, and
perseverative behavior, and have been used in studies of PFC cognitive function[4].
Electrophysiological studies would also be of great utility to provide insight into learning and
memory systems in a mouse model with reduced locomotor activity that confounds interpretation
of many conventional learning and memory tests.
Characterization of behaviors translatable to positive symptoms of SCZ in humans is
limited in general and may be difficult in the HRM/DISC1 model, as many tests rely on
locomotor behaviors as a measure (i.e. augmented locomotor response to NMDA receptor
antagonists and amphetamines)[5]. Sensitivity to psychotomimetic drugs can also be measured in
other tests, including PPI, which may offer a limited avenue to test positive symptoms in these
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mice. Analysis of stereotyped motions may also offer insight into behaviors relevant to
psychomotor agitation in SCZ patients[6]. While our initial tests suggest that hyperactivity may
not be a feature of the HRM/DISC1 as a model for SCZ, it is neither necessary nor realistic for
an animal model to recapitulate every aspect of the disease to improve our understanding of its
pathogenesis.
In several of our tests, the behavioral phenotype of HRM/DISC1 mice resembles that of
the DISC1 line. Notable points where the HRM/DISC1 phenotype appears to be distinct from
either single mutant model include decreased mobility and daily bouts of activity, reduced startle
response, and reduced dendritic outgrowth in immature neurons. The possibility that some of the
similarities are due to the expression of tTa cannot be totally excluded, as all mice from both
DISC1 and HRM/DISC1 groups express tTa, while the WT group was mixed. We did not detect
significant differences between WT and WT/tTa mice in our behavioral tests, but the ability to
detect these differences may be limited by group size. Expanding the diazepam, PV, BrdU and
NeuN studies to include HRM and DISC1 samples will be necessary to develop a more specific
description of the HRM/DISC1 model. We expect that there are likely also changes in GAD67
expression in the remaining PV+ cells in the PFC, and that PV+ interneurons in the hippocampus
may also be affected.
Previous work our group has produced falls at the intersection of these two studies. We
evaluated the potential for CK1 inhibition to rescue cognitive deficits in a mouse model for
Alzheimer’s Disease (AD) expressing human transgenes for mutated amyloid precursor protein
and presenilin-1 (APP-PS1)[7]. We demonstrated that CK1ε/δ inhibition impacts β-amyloid and
expression of circadian proteins, and improves cognition, affect, and social behavior in APP-PS1
mice. While it may achieve some of these effects through reduction of amyloidogenic effects[8,

124

9], it is also possible that the improvement is due to stabilization of PER in the nucleus, and
subsequent stabilization of circadian rhythms, potentially leading to improvement in sleep/wake
cycles and in cognitive processes.
The normal affect and relatively subtle alterations in the circadian rhythms of
HRM/DISC1 mice as a group do not necessarily predispose this model toward use of CK1
inhibition to attempt to rescue these defects. However, patients with SCZ show a wide range of
circadian and sleep disturbances, and the variability in rest/activity patterns we observed between
individual HRM/DISC1 mice suggests that this may also be the case in our model[1]. CK1
inhibition, or other treatments targeting circadian rhythms, are an attractive possibility to
improve the quality of life in a subset of patients with SCZ.
We demonstrated in our study of healthy, adult WT mice that CK1 inhibition has the
potential to improve cognitive performance in the absence of a circadian defect or disease
pathology. It is possible that CK1 inhibitors could be useful as a secondary treatment strategy in
addition to antipsychotics to help address cognitive deficits in SCZ and other neuropsychiatric
disorders[10]. A circadian study of 20 patients with SCZ found pronounced sleep and circadian
disruption in all patients with diverse sleep-wake phenotypes[1]. The authors suggested a
number of mechanisms for impairment in these patients, pointing out that antipsychotic
medications, environmental conditions, and the lack of a daily routine may also be contributing
factors. Isolating the mechanisms of circadian rhythm disruption in patients with SCZ is
confounded by these factors. As circadian disruption in the HRM/DISC1 mouse model is present
in controlled laboratory conditions, this model presents an opportunity to correlate circadian
disruption with other SCZ-related behavioral measures. In future studies, chronotherapeutics like
PF670462 can be administered to HRM/DISC1 mice to attempt to rescue behavioral deficits.
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Furthermore, this model can be used to determine whether a circadian phenotype with a genetic
basis is susceptible to environmental factors that have been associated with SCZ risk. In older
patients with SCZ, more severe sleep and circadian rhythm disturbances are correlated with
poorer performance on neuropsychological tests[11]. If long-term circadian disruption is a
contributing factor to cognitive defects in SCZ, intervention with PF670462 early in the
development of disease symptoms could help improve both short and long term patient
outcomes.
There are a number of exciting routes for continued exploration of both of these projects.
Time-course studies of cognitive behavioral performance in healthy mice treated with CK1
inhibitors will help provide insight about whether the improvement is due to a shift in the
peak/trough times of cognitive performance, or perhaps an effect of stabilization of subtle
circadian disruptions. Expansion of the baseline characterization of the behavioral phenotype of
HRM/DISC1 mice with tests that avoid the confounds we uncovered in these studies will pave
the way for work determining whether these genetic disruptions increase susceptibility to
environmental factors. Together, these studies represent valuable insight into two tools that can
be used to better understand the interactions between circadian rhythms, cognition, and
neuropsychiatric disease.
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